Method for producing human insulin analogs and derivatives thereof in mammalian cells
By co-expressing insulin precursors and modification enzymes in mammalian cells, and directly processing and secreting insulin in cells, the problem of folding and purification difficulties in the prior art is solved, and efficient and low-cost insulin production is achieved.
Patent Information
- Application Number
- CN202380031499.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-10
- Filing Date
- 2023-02-09
- Publication Date
- 2024-11-15
AI Technical Summary
The existing recombinant insulin production systems have problems such as difficulty in correct folding and purification, risk of immune responses, and high cost, and the existing methods have low yields and cumbersome steps.
Using co-expression of insulin precursors and modification enzymes in mammalian cells, pro-insulin is processed into functional insulin through expression vectors, and the post-translational modification ability of the host cell is used to reduce unnecessary enzymatic steps and purification processes, and improve yield and purity. .
It realizes high yield and high purity functional insulin production, simplifies the process flow, reduces costs and protein losses, and improves production efficiency.
Smart Images

Figure CN118973604A_ABST
Abstract
Description
Cross-references
[0001] This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 308,913, filed on February 10, 2022, the entire contents of which are incorporated herein by reference. Description of the XML file submitted electronically
[0002] The contents of the electronic sequence listing (IBTS_001_01WO_SeqList_ST26.xml; size: 32,369 bytes; creation date: February 6, 2023) are incorporated herein by reference in their entirety. Technical Field
[0003] The present disclosure generally relates to methods for producing functional recombinant proteins in their native conformation. The present invention is particularly useful for producing proteins that favor post-translational modifications such as trimming, correct folding, and glycosylation. Background Art
[0004] Insulin is an important polypeptide hormone produced by pancreatic β cells in the islets of Langerhans and is required for maintaining blood glucose homeostasis in mammals (including humans) and other vertebrates. In healthy individuals, increases in blood glucose levels stimulate the secretion of insulin from the β cells of the pancreas. The insulin polypeptide then binds to specific receptors in muscle, liver, and adipose tissue, resulting in increased glucose uptake by these target tissues, increased metabolism, and decreased hepatic glucose production. The cumulative effect of these responses maintains blood glucose concentrations at a constant level.
[0005] There are about 177 million people suffering from diabetes in the world. Among them are about 17 million type I diabetes patients, for whom supplementing the lack of endocrine insulin secretion is the only possible therapy at present, otherwise complications such as ketoacidosis, coma and death within a few weeks will occur. Type I diabetes patients treated with suboptimal doses of insulin will have secondary diseases such as ketoacidosis, blindness, heart disease and renal failure. Despite great progress in transplantation and cell therapy, type 1 diabetes is still uncurable. Type II diabetes is different from type I diabetes in that type II diabetes is relatively rather than absolutely lacking in insulin, but in many cases, especially in the late stage, it is inevitable to use insulin therapy for treatment, and it is also the most favorable type of therapy. In addition, it is estimated that in the next 25 years, the number of individuals diagnosed with diabetes will double to about 300 million (Kjeldsen, T. et al., 2001, Biotechnol. Gen. Eng. Rev. 18: 89-121). However, since the average cost of insulin in the United States has been increasing for many years, the cost of obtaining insulin therapy is also high. Therefore, there is a great need to be able to manufacture human insulin in large quantities in a cost-effective manner to meet the expected growing world demand for insulin.
[0006] Since the development of recombinant DNA technology, many methods for producing insulin, precursors and analogs thereof in genetically modified host cells have been described. There are many recombinant protein production systems, from bacteria, yeast and insect cells to plant cells and mammalian cells. However, existing recombinant insulin production systems and methods have various disadvantages. The prokaryotic production systems commonly used for recombinant production of insulin analogs, such as Escherichia coli (Frank et al., 1981, in Peptides: Proceedings of the 7 thAmerican Peptide Chemistry Symposium (Rich & Gross, ed.), Pierce Chemical Co., Rockford. Ill pp. 729-739; Chan et al., 1981, Proc Natl. Acad. Sci. USA 78: 5401-5404), Saccharomyces cerevisiae (Thim et al., 1986, Proc. Natl. Acad. Sci. USA 83: 6766-6770), cannot provide the correct folding of the expressed polypeptide or establish the disulfide bond connecting the A chain and the B chain in mature insulin. Eukaryotic systems provide improvements, but there are still many disadvantages. For example, high mannosylation in yeast strains can affect the ability of yeast to correctly express glycoproteins. In addition, when the therapeutic protein prepared thereby is administered to a patient, high mannosylation can often even lead to an immune response. In addition, yeast secretion signals are different from mammalian signals, which makes it more difficult to transport mammalian proteins (including human polypeptides) outside the cell, which in turn leads to problems with continuous production and / or separation.
[0007] Wang et al. (Biotechnol. Bioeng., 2001, 73: 74-79) have shown that yeast (such as Pichia pastoris) is suitable for the production of insulin. However, one of the main disadvantages of this system is the post-translational modification of the resulting protein, which is later present in the final product as an impurity that is difficult to purify. In addition, the enzymatic steps used in existing production systems are time-consuming, costly, and introduce additional impurities that must then be removed in further downstream processing steps (such as expensive chromatography steps, etc.).
[0008] Mammalian cells are widely used for protein production due to their ability to carry out numerous post-translational modifications. However, the recombinant production of glycoproteins or proteins comprising at least two (different) subunits in mammalian cells remains a challenge.
[0009] In view of the complex methods, high costs and low yields of existing production systems and methods for recombinant production and purification of biologically active insulin and / or insulin analogs, alternative methods are needed to recombinantly express functional insulin and / or insulin analogs with native conformations. The presently disclosed embodiments address these needs and provide other related advantages. Summary of the invention
[0010] Provided herein are methods and compositions for producing functional recombinant proteins in native conformations in host cell cultures. The disclosed method includes transforming host cells with at least one expression vector to co-express protein precursors (i.e., preproteins or propeptides) and at least one agent (e.g., protease) for processing protein precursors into functional proteins by post-translational modification (e.g., enzymatic cleavage). Non-limiting example proteins that can be produced by the disclosed method include insulin, amylin, gastrin, ghrelin, glucagon, somatostatin, α-MSH, ACTH, β-endorphin or other peptide hormones. In some aspects, the host cell is a mammalian cell selected from the group comprising HEK293 cells, CHO cells, COS and HeLa cells. In other aspects, the host cell is selected from the group comprising algae and yeast.
[0011] According to the present disclosure, the recombinant protein comprises mature insulin or insulin analogs. Specifically, the new and improved methods of the present disclosure relate to a process for preparing at least one insulin analog and / or insulin derivative, the process having the advantages of higher yield and higher purity of the desired product, while reducing the number of steps required to obtain at least one insulin analog and / or insulin derivative. The method disclosed herein relates to an efficient process for producing recombinant human insulin analogs and / or derivatives thereof, the process reducing and / or eliminating the presence of unwanted cleavage byproducts, and also presenting the advantages of eliminating several time-consuming and expensive purification steps.
[0012] In some aspects, the present disclosure provides an improved method for producing insulin analogs or derivatives thereof. In some aspects, the present disclosure provides a method for producing insulin analogs or derivatives thereof in mammalian host cells. Advantageously, the method and composition according to the present disclosure can utilize the more evolved ability of the mammalian cell host mechanism to read, fold and cleave the expressed recombinant insulin analogs in vivo. In addition, the method and composition of the present disclosure utilize agents that can process recombinant insulin analogs in vivo, and introduce them into mammalian cell hosts exogenously, so that mature insulin analogs can be produced without the need for additional digestion, processing and purification steps, to optimize and simplify the process for producing functional insulin and / or insulin analogs. Compared with current / existing production methods, the optimization method and composition of the present disclosure can save material, equipment and time costs, and improve yield by reducing protein loss.
[0013] Therefore, the present disclosure provides a method for producing a functional recombinant protein in its native conformation comprising an insulin analog and / or its derivatives in a mammalian host cell. In a certain aspect, the method includes providing a competent mammalian host cell. According to the present disclosure, the method includes transforming a competent mammalian host cell with an expression vector suitable for expression in a mammalian host cell. The expression vector comprises a heterologous nucleic acid sequence encoding a precursor peptide of at least one human insulin analog or its derivative and / or a modified human insulin pro peptide. In certain aspects, the method includes culturing a transformed mammalian host cell colony in a suitable growth medium under conditions suitable for expressing and secreting a precursor peptide of at least one human insulin analog or its derivative and / or a modified human insulin pro peptide; and harvesting or recovering secreted insulin analogs and / or its derivatives. In certain aspects, the recovery of secreted peptides includes recovering mature processed peptides from the growth medium. In any aspect of the present disclosure, the secreted insulin analog and / or its derivatives are functional insulin analogs and / or its derivatives in their native conformation and are capable of binding to insulin receptor peptides.
[0014] The present disclosure provides an expression vector comprising as operably linked components in the 5' to 3' transcriptional direction: (i) a nucleic acid sequence capable of controlling expression in a mammalian host cell; (ii) a nucleic acid sequence encoding a signal peptide for effectively secreting an insulin analog or a derivative thereof; (iii) optionally, a nucleic acid sequence encoding an N-terminal fusion ligand; (iv) a nucleic acid sequence encoding a modified proinsulin polypeptide; and (v) a nucleic acid sequence encoding one or more agents for processing the modified proinsulin into a functional insulin analog or a derivative thereof. The agent for processing the modified proinsulin into a functional insulin analog or a derivative thereof is selected from the group comprising prohormone convertase 1 / 3 (PC1 / 3), PC2, and carboxypeptidase E (CPE). In some aspects, the agent for processing the modified proinsulin into a functional insulin lispro or a derivative thereof comprises PC1 / 3, CPE, and optionally PC2. In another aspect, the agent for processing the modified proinsulin into a functional insulin glargine or a derivative thereof comprises PC1 / 3 and optionally PC2.
[0015] The present disclosure provides a first and a second expression vector. In some aspects, the first expression vector comprises as an operably connected component in the 5' to 3' transcriptional direction: (i) a nucleic acid sequence capable of controlling expression in mammalian cells; (ii) a nucleic acid sequence encoding a signal peptide for effectively secreting an insulin analog or its derivative; (iii) optionally, a nucleic acid sequence encoding an N-terminal fusion ligand; and (iv) a nucleic acid sequence encoding a modified proinsulin polypeptide. In another aspect, the second expression vector comprises as an operably connected component in the 5' to 3' transcriptional direction: (i) a nucleic acid sequence capable of controlling expression in mammalian cells; and (ii) a nucleic acid sequence encoding one or more agents for processing the modified proinsulin into a functional insulin analog or its derivative. The agent for processing the modified proinsulin into a functional insulin analog or its derivative is selected from the group comprising PC1 / 3, PC2 and CPE. In some aspects, the agent for processing the modified proinsulin and / or proinsulin analogs into functional insulin lispro or its derivatives comprises PC1 / 3, CPE and optionally PC2. In another aspect, the agent for processing modified proinsulin into functional insulin glargine or a derivative thereof comprises PC1 / 3 and optionally PC2.
[0016] The disclosure provides heterologous nucleic acid sequences encoding the precursor peptides of at least one human insulin analog and / or the modified proinsulin peptides, wherein the heterologous nucleic acid sequences are prepared by changing the proinsulin gene by replacing codons at appropriate sites of the natural proinsulin gene. In some aspects, the amino acid residues required for the replacement coding of the codons are replaced. The non-limiting representative examples of the required amino acid replacement are B28Lys, B29Pro human insulin, B28Asp human insulin, A21Gly human insulin, B31Arg, B32Arg human insulin, B31Leu, B32Ala human insulin; B31Leu, B32Ala, desB30 human insulin, B31Phe, B32Leu human insulin and B31Phe, B32Leu, desB30 human insulin.). According to the disclosure, heterologous nucleic acid is prepared by synthesizing the entire DNA sequence encoding at least one human insulin analog.
[0017] In certain aspects, the heterologous nucleic acid encoding a modified proinsulin peptide and / or a precursor peptide of at least one human insulin analog or derivative thereof encodes the B chain of human insulin or its analog, the A chain of human insulin or its analog, and the C peptide linking the B chain and the A chain together.
[0018] According to the disclosure, the heterologous nucleic acid sequence of the precursor peptide of encoding at least one human insulin analog or its derivative also comprises the nucleotide sequence that coding is used for the proinsulin of modification to be processed into one or more agents of functional insulin analog or its derivative.In some aspects, the one or more agents that are used for the proinsulin of modification to be processed into functional insulin analog or its derivative comprise PC 1 / 3, PC2, CPE and effectively block the active blocker of endogenous CPE.In some aspects, mammalian host cell is modified to express and is used for the proinsulin of modification to be processed into one or more agents of functional insulin analog or its derivative.
[0019] The present disclosure provides a method, which includes a first expression vector comprising a heterologous nucleic acid sequence encoding a precursor peptide of at least one human insulin analog or derivative thereof and / or a modified human insulin propeptide, and a second expression vector comprising a heterologous nucleic acid sequence encoding one or more agents of the modified proinsulin being processed into functional insulin transforming competent mammalian host cells. In some aspects, one or more agents for processing the modified proinsulin into functional insulin include endoproteinases, carboxypeptidase E, and a blocker that effectively blocks endogenous carboxypeptidase E activity. In one aspect, the endoproteinase comprises PC1 / 3 and PC2. In some aspects, the mammalian host cell is modified to express one or more agents for processing the modified proinsulin into functional insulin analog or derivative thereof.
[0020] In some aspects, the heterologous nucleic acid sequence encodes a peptide that is at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to the amino acid sequence shown in SEQ ID: No.1, SEQ ID: No.2; SEQ ID: No.3 and SEQ ID: No.4.
[0021] In certain aspects, the heterologous nucleic acid sequence encodes a peptide having an amino acid sequence as shown in SEQ ID: No.1, SEQ ID: No.2; SEQ ID: No.3 and SEQ ID: No.4.
[0022] According to the present disclosure, heterologous nucleic acid also encodes one or more agents for processing modified proinsulin into functional insulin. In some aspects, one or more agents have at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher) identity with the amino acid sequence shown in SEQ ID: No.5, SEQ ID: No.6; SEQ ID: No.7 and SEQ ID: No.8. In some aspects, the one or more agents have the amino acid sequence shown in SEQ ID: No.5, SEQ ID: No.6; SEQ ID: No.7 and SEQ ID: No.8.
[0023] A heterologous nucleic acid sequence encoding at least one insulin analog or derivative thereof is inserted into a suitable expression vector which, when transferred into a suitable host organism, expresses the desired product. The expressed product is secreted from the host cell and recovered from the culture medium.
[0024] In some aspects, the disclosure provides polynucleotides encoding peptides comprising modified human proinsulin or human proinsulin analogs or derivatives thereof; and one or more agents for processing modified proinsulin into functional insulin. In some aspects, the heterologous nucleic acid sequence encoding the peptide comprising modified human proinsulin or human proinsulin analogs or derivatives thereof has at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher) identity with the amino acid sequence shown in SEQ ID: No.1, SEQ ID: No.2; SEQ ID: No.3 and SEQ ID: No.4. In some aspects, the modified human proinsulin or human proinsulin analogs or derivatives thereof encoded by the peptide have the amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2; SEQ ID NO: 3 and SEQ ID NO: 4. In some aspects, the polynucleotide further comprises a heterologous nucleic acid sequence encoding one or more agents for processing the modified proinsulin into functional insulin. In some aspects, the polynucleotide further comprises a heterologous nucleic acid sequence encoding a blocking agent that effectively blocks the activity of endogenous carboxypeptidase E. The one or more agents for processing the modified proinsulin into functional insulin include one or more endoproteases and carboxypeptidase E. One or more endoproteases are selected from PC1 / 3, PC2. In some aspects, one or more agents have at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher) identity with the amino acid sequence shown in SEQ ID: No.5, SEQ ID: No.6; SEQ ID: No.7 and SEQ ID: No.8. In certain aspects, the one or more agents have an amino acid sequence as shown in SEQ ID: No.5, SEQ ID: No.6; SEQ ID: No.7 and SEQ ID: No.8.
[0025] The disclosure further relates to an expression vector comprising a polynucleotide encoding a peptide and a modified mammalian host cell, wherein the peptide comprises modified human proinsulin or human proinsulin analog or derivatives thereof and at least one agent for processing the modified proinsulin into functional insulin. In some aspects, the mammalian host cell comprises genetic modification to promote formation in the cytoplasm for processing the modified proinsulin into a stable disulfide bond for functional insulin. In some aspects, the disclosure further provides a human cell comprising an expression vector encoding a peptide, wherein the peptide comprises modified human proinsulin or human insulin analog or derivatives thereof. In some aspects, the disclosure provides a human cell comprising an expression vector encoding a peptide, wherein the peptide comprises modified human proinsulin or human proinsulin analog or derivatives thereof and at least one agent for processing the modified proinsulin into functional insulin.
[0026] In some aspects, the present disclosure provides a method for making insulin analogs and / or derivatives thereof, comprising producing a mammalian host cell that expresses and secretes insulin, comprising transforming the mammalian host cell with an expression vector that co-expresses a modified proinsulin polypeptide and one or more agents for processing the modified proinsulin into a functional insulin analog or derivative thereof. In another aspect, the present disclosure provides a method for making insulin analogs and / or derivatives thereof, comprising producing a competent mammalian host cell capable of making and secreting insulin, comprising transforming the host cell with a first expression vector expressing a proinsulin polypeptide and a second expression vector expressing one or more agents for processing proinsulin and / or proinsulin analogs into functional insulin analogs or derivatives thereof.
[0027] In some aspects, the disclosure provides a method for making a fast-acting insulin analog and / or its derivatives, comprising transforming a mammalian host cell with a recombinant expression vector, the recombinant expression vector comprising (i) a nucleic acid sequence capable of controlling expression in a mammalian host cell; (ii) a nucleic acid sequence encoding a signal peptide for effective secretion of an insulin analog or its derivatives; (iii) optionally, a nucleic acid sequence encoding an N-terminal fusion ligand; (iv) a nucleic acid sequence encoding a modified proinsulin polypeptide; (v) a nucleic acid sequence encoding PC1 / 3; (vi) a nucleic acid sequence encoding CPE; and (vii) optionally, a nucleic acid sequence encoding PC2. In some aspects, the fast-acting insulin analog is insulin lispro.
[0028] In some aspects, the present disclosure provides a method for making a long-acting insulin analog and / or its derivatives, comprising transforming a mammalian host cell with a recombinant expression vector, wherein the recombinant expression vector comprises (i) a nucleic acid sequence capable of controlling expression in a mammalian host cell; (ii) a nucleic acid sequence encoding a signal peptide for effective secretion of an insulin analog or its derivatives; (iii) optionally, a nucleic acid sequence encoding an N-terminal fusion ligand; (iv) a nucleic acid sequence encoding a modified proinsulin polypeptide; (v) a nucleic acid sequence encoding PC1 / 3; and (vi) optionally, a nucleic acid sequence encoding PC2. In some aspects, the long-acting insulin analog is insulin glargine.
[0029] In some aspects, the method for making long-acting insulin analogs and / or its derivatives also includes the optional step of blocking endogenous carboxypeptidase E (CPE) activity. In some aspects, the step of blocking endogenous carboxypeptidase E activity includes introducing deletion or mutation into endogenous CPE, resulting in expression or reduction or elimination of activity. In some aspects, the host cell can be a CRISPR-modified host cell with reduced or eliminated CPE activity. For example, such host cells can be produced by using CRISPR to reduce or eliminate CPE expression or by allowing catalytically inactivated CPE expression. For example, the serine at position 202 of the sequence shown in SEQ ID NO:9 can be mutated to, for example, proline. In some aspects, the reduction or elimination of CPE activity can be conditional or inducible (for example, in the form of a Cre-dependent construct). In some aspects, the step of blocking endogenous carboxypeptidase E activity includes co-expressing a mutated CPE in a mammalian host cell, wherein the mutated CPE is located at a position selected from the group consisting of 72H, 75E, 147R, 192H, 202S, 243Y and 296E comprising the sequence shown in SEQ ID NO:9 and has at least one mutation. In some aspects, the nucleic acid sequence encoding the mutated CPE is contained in an expression vector for the co-expressed modified proinsulin polypeptide. In another aspect, the nucleic acid sequence encoding the mutated CPE is contained in a separate expression vector. In some aspects, the present disclosure provides a host cell expressing a catalytically inactive CPE, wherein the CPE binds to a substrate but does not cleave a peptide bond, wherein the catalytically inactive CPE is located at a position selected from the group consisting of 72H, 75E, 147R, 192H, 202S, 243Y and 296E comprising the sequence shown in SEQ ID NO:9 and has at least one mutation. In some aspects, the step of blocking endogenous CPE activity comprises adding a blocking agent selected from the group consisting of dopamine quinine, dopamine, norepinephrine, epinephrine, potato carboxypeptidase inhibitor (PCI), a 9-mer peptide designated CPI-2KR, and a peptide encoding a decoy arginine sequence. The decoy arginine peptide disclosed herein comprises a polymer having a length of 3 amino acids and having an amino acid sequence having at least 70% amino acid sequence identity with an extension of the C-terminus of the long-acting insulin B chain, such as the sequence shown in SEQ ID NO: 15. The decoy arginine peptide is configured to mimic the extension of the C-terminus of the long-acting insulin B chain to bind to endogenous CPE, so that it prevents endogenous CPE from removing the extension of the C-terminus of the B chain.
[0030] In some aspects, the disclosure relates to methods for obtaining purified biologically active heterologous recombinant proteins expressed in mammalian expression systems. In some aspects, the method comprises culturing a host cell transformed by at least one vector under suitable growth medium and conditions suitable for recombinant protein expression, the vector comprising a heterologous nucleic acid sequence encoding a peptide having at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher) identity with the amino acid sequence shown in SEQ ID: NO.1, SEQ ID: NO.2; SEQ ID: NO.3 or SEQ ID: NO.4. In some aspects, the method comprises culturing a host cell transformed by at least one vector comprising a nucleotide sequence encoding a peptide having an amino acid sequence as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID: No.4. In some aspects, the vector comprising a heterologous nucleic acid encoding a peptide also encodes one or more agents for processing the heterologous protein into a mature functional protein. In some aspects, the one or more agents have at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity with the amino acid sequence shown in SEQ ID: No.5, SEQ ID: NO.6; SEQ ID: NO.7 or SEQ ID: NO.8. In some aspects, the one or more agents have an amino acid sequence as shown in SEQ ID: No.5, SEQ ID: NO.6; SEQ ID: NO.7 or SEQ ID: NO.8.
[0031] In a certain aspect, the method includes reclaiming or harvesting the expressed recombinant protein, wherein the step of reclaiming the recombinant protein includes separating the protein from the culture medium to produce the reclaimed recombinant protein preparation. In some aspects, the method also includes purifying the recombinant protein preparation recovered by contacting the recovered protein preparation with a chromatographic matrix to remove at least one related impurity. Purification is carried out by applying a polar organic buffer solvent in an aqueous phase containing an organic acid buffer and precipitating the eluted protein. In any aspect of the present disclosure, the mature functional recombinant protein is a human insulin analog and / or its derivative. In any aspect of the present disclosure, recombinant human insulin comprises an A chain with an amino acid sequence as shown in SEQ ID NO:10, and a B chain with an amino acid sequence as shown in SEQ ID NO:11. In another aspect, recombinant human insulin comprises an A chain with an amino acid sequence as shown in SEQ ID NO:12, and a B chain with an amino acid sequence as shown in SEQ ID NO:13. In another aspect, recombinant human insulin comprises an A chain with an amino acid sequence as shown in SEQ ID NO:14, and a B chain with an amino acid sequence as shown in SEQ ID NO:14. In certain aspects, the recombinant human insulin comprises an A chain having an amino acid sequence that is at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to the amino acid sequence shown in SEQ ID NO:10, and a B chain having an amino acid sequence that is at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to the amino acid sequence shown in SEQ ID NO:11. In certain aspects, the recombinant human insulin comprises an A chain having an amino acid sequence that is at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to the amino acid sequence shown in SEQ ID: NO.12, and a B chain having an amino acid sequence that is at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to the amino acid sequence shown in SEQ ID NO:13.In some aspects, the recombinant human insulin comprises an A chain having an amino acid sequence that is at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to the amino acid sequence shown in SEQ ID: NO.14, and a B chain having an amino acid sequence that is at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to the amino acid sequence shown in SEQ ID NO:15.
[0032] According to the present disclosure, the yield of purified insulin analogs and / or derivatives thereof is 75%-100%. According to another aspect of the present disclosure, the yield of purified insulin analogs and / or derivatives thereof is 75%-80%, 80%-85%, 85%-90%, 90%-95% or 95%-100%.
[0033] The present disclosure provides an integrated and continuous process for manufacturing recombinant human insulin analogs and / or derivatives thereof, the process comprising: (i) culturing mammalian cells that secrete recombinant human insulin analogs in a perfusion bioreactor containing a liquid culture medium under conditions that allow the cells to secrete the recombinant insulin analogs and / or derivatives thereof into the culture medium, and wherein a substantially cell-free volume of the culture medium is continuously or periodically removed from the perfusion bioreactor and fed to a first periodic countercurrent chromatography system (PCCS1); and (ii) capturing the recombinant insulin analogs and / or derivatives thereof from the culture medium using the PCCS1. , wherein the PCCS1 eluate containing recombinant insulin analogs and / or derivatives thereof is continuously fed to a second periodic countercurrent chromatography system (PCCS2); and (iii) purifying the recombinant insulin analogs and / or derivatives thereof using PCCS2, wherein the purification is performed using a resin in PCCS2 having a chemical structure different from that of the resin in PCCS2 used for polishing, and the eluate from PCCS2 is insulin analogs and / or derivatives thereof; and wherein the process is integrated and runs continuously from the culturing step to the eluate from PCCS2 being insulin analogs and / or derivatives thereof. In some aspects, the recombinant human insulin analog secreting mammalian cells are transformed with at least one vector comprising a heterologous nucleic acid sequence encoding a peptide having at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity with the amino acid sequence shown in SEQ ID: NO.1, SEQ ID: NO.2; SEQ ID: NO.3 or SEQ ID: NO.4. In some aspects, the recombinant human insulin analog secreting mammalian cells are transformed with at least one vector comprising a heterologous nucleic acid sequence encoding a peptide comprising an amino acid sequence as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID: No.4.
[0034] Human insulin analogs and derivatives thereof according to the present disclosure can be used to treat insulin-sensitive states. Thus, human insulin analogs and derivatives thereof can be used to treat type 1 diabetes, type 2 diabetes, and hyperglycemia, such as is sometimes seen in severely injured people and those who have undergone major surgery.
[0035] In another aspect, the disclosure relates to pharmaceutical formulations comprising human insulin analogs and suitable pharmaceutically acceptable adjuvants and additives, such as one or more agents suitable for stabilization, preservation or isotonicity.
[0036] Thus, in another aspect, the present disclosure provides a method for treating diabetes in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a human insulin analog obtained by the method disclosed herein.
[0037] From the following specific embodiments, other features and advantages of the present disclosure will become apparent. However, it should be understood that although the specific embodiments and specific examples describe preferred aspects, they are only given by way of example, because according to this specific embodiment, various changes and modifications within the spirit and scope of the present disclosure will become apparent to those skilled in the art. BRIEF DESCRIPTION OF THE DRAWINGS
[0038]
[0013] The embodiments disclosed herein will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings.
[0039] Figure 1 The history of insulin production is depicted, and further a schematic diagram of the strategy for synthesizing insulin analogs by the methods of the present disclosure is provided. Details of the process are provided in Examples 1-3.
[0040] Figure 2A-2B The processing sites for the production of mature insulin analogs in mammalian cells are shown.
[0041] Figure 3 Insulin synthesis in pancreatic beta cells is described.
[0042] Figure 4 Shown is the small-scale production (50 ml) of lispro and glargine harvested from 20-fold concentrated supernatant of HEK cells transformed with a vector comprising a heterologous nucleic acid sequence encoding the corresponding insulin analog and an agent (Furin) required for processing the recombinant protein into a mature, functional insulin analog.
[0043] Figure 5 The superiority of agents used in humans (PC1 / 3, PC2 and carboxypeptidase E) compared to furin in cleaving the α, β and c chains of recombinant insulin to produce mature insulin for the manufacture of insulin lispro analogs is shown.
[0044] Figure 6 The superiority of agents used in humans (PC1 / 3, PC / 2 and mutant carboxypeptidase E) compared to furin in cleaving the α, β and c chains of recombinant insulin to produce mature insulin for the manufacture of insulin glargine analogs is shown.
[0045] Figures 7A-7DShown are mass spectrometric analyses of the insulin analog Scn-lispro produced using: PC1 and CPE (non-reduced) (7A); PC1 and CPE (reduced) (7B); PC1 (non-reduced) (7C); and PC1 (reduced) (7D).
[0046] Figures 8A-8D Shown are mass spectrometric analyses of the insulin analog glargine produced by the methods of the present disclosure using: PC1 and CPE (non-reduced) (8A); PC1 and CPE (reduced) (8B); PC1 (non-reduced) (8C); and PC1 (reduced) (8D). DETAILED DESCRIPTION
[0047] It is readily understood that the embodiments generally described herein are exemplary. The following description of the various embodiments is not intended to limit the scope of the present disclosure, but is merely representative of the various embodiments. In addition, without departing from the scope of the present disclosure, those skilled in the art may change the order of steps or actions of certain methods disclosed herein. In other words, unless the correct operation of the embodiment requires a specific order of steps or actions, the order or use of specific steps or actions may be modified.
[0048] Before describing the present disclosure in more detail, it will be helpful to understand the present disclosure to provide definitions of certain terms used herein. Additional definitions are also set forth in the present disclosure.
[0049] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which the disclosure belongs. Where permitted, all patents, applications, published applications and other publications, including nucleic acid and polypeptide sequences from GenBank, SwissPro and other databases mentioned in the disclosure are incorporated herein by reference in their entirety.
[0050] In the present disclosure, unless otherwise stated, any concentration range, percentage range, ratio range or integer range should be understood to include the value of any integer within the range, and where appropriate, include fractions thereof (such as tenths and hundredths of integers). In addition, unless otherwise stated, any numerical range related to any physical feature (such as polymer subunits, size or thickness) described herein should be understood to include any integer within the range.
[0051] As used herein, the term "about" refers to a value or value range that is greater than or less than 10%, but is not intended to specify any value or value range as only this broader definition. Each value or value range preceding the term "about" is also intended to cover the embodiments of the absolute value or value range.
[0052] It should be understood that, as used herein, the terms "a" and "an" refer to "one or more" of the listed components. The use of alternatives (e.g., "or") should be understood to refer to one, both, or any combination of the alternatives. As used herein, the terms "including," "having," and "comprising" are used synonymously, and these terms and variations thereof are intended to be construed as non-limiting.
[0053] "Optional" or "optionally" means that the subsequently described element, component, event or circumstance may or may not occur, and that the description includes instances where the element, component, event or circumstance occurs and instances where it does not.
[0054] As used herein, the term "prodrug" and / or "proinsulin" and / or "propeptide" is defined as any compound that is chemically modified before exhibiting its pharmacological effect.
[0055] As used herein, "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those amino acids encoded by the genetic code, as well as those amino acids that are later modified, for example, hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as naturally occurring amino acids, i.e., an α-carbon bound to a hydrogen, carboxyl, amino, and R groups, for example, homoserine, norleucine, methionine sulfoxide, methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimetics refer to compounds that have a structure that is different from the general chemical structure of an amino acid, but that function in a manner similar to that of a naturally occurring amino acid.
[0056] In addition, "amino acid" encompasses any molecule containing an amino and carboxyl functional group, wherein the amino and carboxyl groups are attached to the same carbon (the alpha carbon). The alpha carbon may optionally have one or two additional organic substituents. For the purposes of this disclosure, amino acid names that do not specify their stereochemistry are intended to encompass either the L or D form of the amino acid, or a racemic mixture. However, where an amino acid is named by its three letter code and includes a superscript number, the D form of the amino acid is designated by including a lowercase d before the three letter code and the superscript number (e.g., dLys -1 ), which lacks the lowercase d (e.g., Lys -1) is intended to designate the natural L form of an amino acid. In this nomenclature, the inclusion of superscript numbers designates the position of an amino acid in the insulin analog sequence, wherein the amino acids within the insulin analog sequence are named by positive superscript numbers numbered consecutively from the N-terminus. Additional amino acids attached to the insulin analog peptide at the N-terminus or via a side chain are numbered starting at 0 and increasing in negative integer values as they are further removed from the insulin analog sequence. For example, the amino acid position within a dipeptide prodrug attached to the N-terminus of an insulin analog is named aa -1 -aa 0 - Insulin analogs, where aa 0 represents the carboxyl terminal amino acid of the dipeptide, and aa -1 Name the amino-terminal amino acid of the dipeptide.
[0057] As used herein, "protein", "polypeptide" or "peptide" refers to a polymer of amino acid residues. Proteins apply to naturally occurring amino acid polymers, as well as amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of the corresponding naturally occurring amino acids and non-naturally occurring amino acid polymers.
[0058] As used herein, an "effective" amount or "therapeutically effective amount" of an insulin analog refers to a non-toxic but sufficient amount of an insulin analog to provide the desired effect. For example, one desired effect is the prevention or treatment of hyperglycemia. An "effective" amount varies from subject to subject, depending on the age and general condition of the individual, the mode of administration, etc. Therefore, it is not always possible to specify an exact "effective amount". However, an appropriate "effective" amount in any individual case can be determined by a person of ordinary skill in the art using routine experimentation.
[0059] As used herein, the term "nucleic acid sequence" refers to a sequence of nucleoside or nucleotide monomers comprising naturally occurring bases, sugars, and intersugar (backbone) bonds. The term also includes modified or substituted sequences comprising non-naturally occurring monomers or portions thereof. The nucleic acid sequences of the present disclosure may be deoxyribonucleic acid sequences (DNA) or ribonucleic acid sequences (RNA) and may include naturally occurring bases comprising adenine, guanine, cytosine, thymidine, and uracil. The sequence may also contain modified bases. Examples of such modified bases include azaadenine and deazaadenine, guanine, cytosine, thymidine, and uracil; as well as xanthine and hypoxanthine.
[0060] Unless otherwise expressly stated, as used herein, "at least about" the sequence identity of the percentage indicated includes ±20% of the percentage indicated, and each integer and non-integer percentage above the specified percentage. Thus, "at least about 85%" identity to a reference sequence (e.g., any one of SEQ ID NOs.: 1-4) includes about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the reference sequence, and also includes all non-integer percentages between two integer percentages (e.g., 92.5%, 99.1%, etc.).
[0061] The terms "nucleic acid sequence encoding insulin" and "nucleic acid sequence encoding an insulin analog" or "nucleic acid sequence encoding an insulin polypeptide or a modified insulin peptide" or "proinsulin" are used interchangeably herein and refer to any and all nucleic acid sequences encoding insulin polypeptides, including but not limited to the proinsulin polypeptides listed in Table 2 (SEQ ID NO: 1, SEQ ID: NO.: 2, SEQ ID: NO.: 3 and SEQ ID: No. 4) and any mammalian insulin polypeptide and any nucleic acid sequence encoding proinsulin, preproinsulin peptides and analogs and / or derivatives thereof. The term "processing agent" refers to any and all nucleic acid sequences encoding agents required for processing proinsulin into mature functional insulin, including but not limited to the polypeptides listed in Table 3 (SEQ ID NO: 5, SEQ ID: NO.: 6, SEQ ID: NO.: 7 and SEQ ID: No. 8).
[0062] In vivo, human insulin polypeptide is produced as a single 110 amino acid polypeptide chain precursor (preproinsulin), which includes a 24 amino acid presequence located at the N-terminus, which is cleaved immediately after the biosynthesis of the chain is completed to produce proinsulin (Steiner, DF 2000. J. Ped. Endocrinol. Metab. 13: 229-239). Proinsulin has a BCA structure, in which the C peptide chain connects the C-terminal amino acid of the B chain to the N-terminal amino acid residue in the A chain. In the packaging process of hormone secretion, the C peptide is cleaved and removed by prohormone convertases PC2 and PC1 / PC3 (Steiner, DF 2000. J. Ped. Endocrinol. Metab. 13: 229-239), thereby producing mature or active human insulin, which is a 51 amino acid protein comprising two polypeptide chains A (length of 21 amino acids) and B (length of 30 amino acids) connected by two interchain disulfide bonds. The A and B chains are linked together by two disulfide bonds between the Cys residues at positions A7 and B7 and A20 and B19, respectively. In addition, the biologically active insulin molecule has an internal (intrachain) disulfide bridge between the Cys residues at positions A6 and A11.
[0063] Nucleic acid sequences encoding insulin polypeptides or peptides also include any and all nucleic acid sequences that (i) encode a polypeptide substantially identical to an insulin polypeptide sequence set forth herein; or (ii) hybridize to any nucleic acid sequence set forth herein under at least moderately stringent hybridization conditions, or hybridize to it under at least moderately stringent conditions except when synonymous codons are used.
[0064] As used herein, the term "proinsulin" is a protein having the following formula, wherein: A is the A chain of insulin or a functional derivative thereof; B is the B chain of insulin or a functional derivative thereof having an ε-amino group; and C is a connecting peptide of proinsulin. Preferably, proinsulin is the A chain of human insulin, the B chain of human insulin, and C is a native connecting peptide. When proinsulin is a native sequence, proinsulin possesses three free amino groups: phenylalanine (1) (α-amino), lysine (29) (ε-amino) and lysine (64) (ε-amino). As used herein, "proinsulin" refers to an insulin polypeptide comprising a connecting peptide or "C-peptide" connecting the B insulin polypeptide chain and the A insulin polypeptide chain. In native human insulin, the C-peptide is a 31 amino acid residue polypeptide chain connecting residue B30 and residue A1. The term "preproinsulin" refers to a proinsulin molecule that additionally comprises an N-terminal signal sequence that directs translation on the ER ribosome.
[0065] As used herein, the term "insulin analog" is a protein that exhibits insulin activity of formula AB, wherein: A is insulin chain A (α) or a functional derivative of insulin chain A; B is insulin chain B (β) or a functional derivative of insulin chain B having an ε-amino group, and at least one of A or B contains an amino acid modification of the natural sequence. Table 1 shows the A chain and B chain sequences of exemplary insulin analogs.
[0066] In the present disclosure, whenever the term insulin is used in the plural or generic sense, it is intended to cover naturally occurring insulin and insulin analogs and derivatives thereof.
[0067] As used herein, "insulin polypeptide" refers to a compound having a molecular structure similar to human insulin, comprising disulfide bridges between Cys.sup.A7 and Cys.sup.B7 and between Cys.sup.A20 and Cys.sup.B19 and an internal disulfide bridge between Cys.sup.A6 and Cys.sup.A11, and having insulin activity.
[0068] Insulin peptides include, but are not limited to, human insulin; porcine insulin; human IGF-1; insulin-like growth factor II (69-84); human insulin-like growth factor II (68-102); human insulin-like growth factor II (105-128); [AspB28] human insulin; [LysB28] human insulin; [LeuB28] human insulin; [Va1B28] human insulin; [AlaB28] human insulin; [AspB28, ProB29] human insulin; [LysB28, ProB29] human insulin; [LeuB28, ProB29] human insulin; [Va1B28, ProB29] human insulin; [AlaB28, ProB29] human insulin; [GlyA21] human insulin; [GlyA21GlnB3] human insulin; [AlaA21] human insulin; [AlaA21 Gln.sup.B3] human insulin; [GlnB3] human insulin; [GlnB30] human insulin; [GlyA21 GluB30] human insulin; [GlyA21 GlnB3 GluB30] human insulin; [GlnB3 GluB30] human insulin; B22B30 human insulin; B23B30 human insulin; B25B30 human insulin; B26B30 human insulin; B27B30 human insulin; B29B30 human insulin; A chain of human insulin and B chain of human insulin.
[0069] As used herein, the terms "precursor peptide of human insulin analog" and "modified proinsulin polypeptide" are used interchangeably herein and refer to the precursor peptide of any and all insulin polypeptides, including the insulin polypeptides and / or peptides listed in Table 1 and polypeptide molecules comprising an amino acid residue sequence (i) substantially identical to the amino acid sequence constituting any insulin polypeptide and / or insulin peptide shown herein, or (ii) encoded by a nucleic acid sequence capable of hybridizing under at least moderate stringency conditions with any insulin encoding nucleic acid sequence shown herein or capable of hybridizing under at least moderate stringency conditions with any insulin encoding nucleic acid sequence shown herein (except using synonymous codons). The terms insulin and insulin polypeptides include proinsulin polypeptides and miniinsulin polypeptides, analogs and derivatives thereof. The insulin analog polypeptides are preferably of human origin.
[0070] The disclosure contemplates certain derivatives or other substitutions of insulin analogs. It is therefore possible to derive one or more functional groups in an amino acid residue. Examples of such derivatizations are the conversion of acidic groups in the insulin molecule known per se into ester or amide groups, the conversion of alcohol groups into alkoxy groups or vice versa, and selective deamidation. For example, A21Asn can be deamidated to A21Asp by hydrolysis in an acidic medium, or B3Asn can be deamidated to B3Asp in a neutral medium.
[0071] The insulin analogs of the present invention can also be modified by adding or removing amino acid residues at the N-terminus or C-terminus. The insulin analogs of the present disclosure can lack up to four amino acid residues at the N-terminus of the B chain and lack up to five amino acid residues at the C-terminus of the B chain without significantly affecting the overall properties of the insulin analogs. Examples of such modified insulin analogs are insulin analogs lacking a B1Phe amino acid residue or a B30Thr amino acid residue.
[0072] Furthermore, naturally occurring amino acid residues may be added to one or more of the termini of the polypeptide chain provided that this does not significantly affect the overall properties and actions of the insulin.
[0073] Such deletion or addition of the polypeptide chain terminal of the insulin analog of the present invention can be implemented in vitro on the insulin analog with amino acid substitution according to the disclosure. Alternatively, the gene of the insulin analog according to the disclosure can be modified by adding or removing the codon corresponding to the additional amino acid residue or the missing amino acid residue at the polypeptide chain terminal, respectively.
[0074] The term "modified polynucleotide" herein refers to a polynucleotide sequence that has been altered to contain at least one mutation to encode a "modified" protein. In some cases, the use of the term "polynucleotide" is not associated with "modified", which does not exclude embodiments of modified polynucleotides.
[0075] As used herein, the terms "protease" and "proteolytic activity" refer to proteins or peptides that exhibit the ability to hydrolyze peptides or substrates having peptide bonds.
[0076] The term "oligonucleotide" is used for nucleic acid molecules DNA (or RNA) of less than 100 nucleotides in length.
[0077] "Transformation" refers to the introduction of DNA into an organism, ie, a host organism, so that the DNA can replicate either as an extrachromosomal element or by chromosomal integration.
[0078] Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. General aspects of transformation of mammalian cell host systems are described by Axel in US Pat. No. 4,399,216, issued Aug. 16, 1983.
[0079] As is clear from the context, "cell" or "cell culture" or "recombinant host cell" or "host cell" are often used interchangeably. These terms include the direct subject cell expressing the desired protein of the invention, and of course its progeny. It is understood that due to accidental mutation or environmental differences, not all progeny are completely identical to the parent cell. However, such modified progeny are also included in these terms, as long as the progeny retain the relevant characteristics conferred on the originally transformed cell.
[0080] The term "express" and the verb "express" refer to the transcription of a DNA sequence and / or the translation of a transcribed mRNA in a host organism to produce a pre-protein, ie, excluding post-translational processes.
[0081] As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid connected thereto. The term "expression vector" includes a plasmid, cosmid or phage capable of synthesizing a test protein encoded by a corresponding recombinant gene carried by the vector. Preferred vectors are those capable of autonomous replication and / or expression of nucleic acids connected thereto. In this specification, "plasmid" and "vector" are used interchangeably because plasmids are the most commonly used vector forms. In addition, the present invention is intended to include expression vectors of such other forms that play an equivalent function and subsequently become known in the art.
[0082] "Promoter" is a regulatory nucleotide sequence that stimulates transcription. Those skilled in the art of genetic engineering will understand these terms. Similar to promoters, "promoter elements" stimulate transcription but constitute subfragments of larger promoter sequences.
[0083] As used herein, the term "operably linked" refers to the combination of two or more nucleic acid fragments on a single vector so that the function of one nucleic acid fragment is affected by the other. For example, a promoter is operably linked to a coding sequence (i.e., a nucleotide sequence encoding a protein or preprotein) when the promoter is capable of affecting the expression of the coding sequence, i.e., the coding sequence is under the transcriptional control of the promoter.
[0084] The term "post-translational processing" or "post-translational modification" refers to the modification steps to which a pre- or prepro-protein is subjected to yield the mature protein in the cell or in an extracellular compartment.
[0085] "Signal peptide" is a cleavable signal sequence of amino acids present in the preprotein or preproprotein form of a secretable protein. Proteins transported across cell membranes (i.e., "secreted") usually have an N-terminal sequence rich in hydrophobic amino acids, usually about 15 to 30 amino acids long. In the process of passing through the membrane, the signal sequence is sometimes cleaved by a signal peptidase (Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P. (ed.), Molecular Biology of the Cell, 4th edition, 2002, Garland Science Publishing). Many sources of signal peptides are well known to those skilled in the art, and may include, for example, the amino acid sequence of the alpha factor signal peptide from yeast saccharomyces cerevisiae, etc. In general, the preprotein N-terminal of substantially any secreted protein is a potential source of signal peptides suitable for the present disclosure. The signal peptide can also be a dichotomous peptide comprising two signal peptides that guide the preprotein to the first cell compartment and the second cell compartment. In the process of the secretory pathway, the dichotomous signal peptide is gradually cleaved.
[0086] The preprotein with an N-terminal signal peptide is directed into the "secretory pathway". The secretory pathway includes post-translational processing and ultimately leads to the secretion of the protein. Glycosylation and disulfide bond formation are part of the secretory pathway prior to secretion.
[0087] The term "substantially identical" means that two polypeptide sequences are preferably at least 75% identical, more preferably at least 85% identical, and most preferably at least 95% identical, such as 96%, 97%, 98% or 99% identical. In order to determine the percent identity between two polypeptide sequences, the amino acid sequences of the two sequences are aligned, preferably using the Clustal W algorithm (Thompson, JD, Higgins DG, Gibson TJ, 1994, Nucleic Adds Res. 22 (22): 4673-4680, and the BLOSUM 62 scoring matrix (Henikoff S. and Henikoff JG, 1992, Proc. Natl. Acad. Sci. USA 89:10915-10919), and the gap opening penalty is set to 10 and the gap extension penalty is set to 0.1, so that the highest order match is obtained between the two sequences, and at least 50% of the total length of one sequence is involved in the comparison. Other methods that can be used for aligning sequences are the alignment method of Needleman and Wunsch (J. Mol. Biol., 1970, 48:443), which was revised by Smith and Waterman (Adv. Appl. Math., 1981, 2:482), so that the highest order match is obtained between the two sequences, and the number of identical amino acids between the two sequences is determined. Other methods for calculating the percent identity between two amino acid sequences are generally recognized in the art and include, for example, the method described by Carillo and Lipton (SIAM J. Applied Math., 1988, 48:1073) and in Computational Molecular Biology, Lesk, ed. Oxford University Press, New York, 1988, Biocomputing: Informatics and Genomics Projects. In general, such calculations will be performed using a computer program. Computer programs that can be used in this regard include, but are not limited to, GCG (Devereux et al., Nucleic Adds Res., 1984, 12: 387) BLASTP, BLASTN, and FASTA (Altschul et al., J. Molec. Biol., 1990: 215: 403).
[0088] "At least moderately stringent hybridization conditions" refer to conditions selected to promote selective hybridization between two complementary nucleic acid molecules in a solution. Hybridization can occur on all or part of a nucleic acid sequence molecule. The hybridization portion is typically at least 15 (e.g., 20, 25, 30, 40, or 50) nucleotides in length. Those skilled in the art will recognize that the stability of a nucleic acid duplex or hybrid is determined by Tm, which is a function of sodium ion concentration and temperature in a sodium-containing buffer (Tm = 81.5°C. -16.6 (Log10 [Na+]) + 0.41 (% (G+C) -600 / 1), or similar equations). Therefore, the parameters that determine hybridization stability in washing conditions are sodium ion concentration and temperature. Additional guidance on hybridization conditions can be found in the following literature: Current Protocols in Molecular Biology, John Wiley & Sons, NY, 1989, 6.3.1.-6.3.6 and Sambrook et al., Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989, Vol. 3. Table 1 - Insulin analogs
[0089] As used herein, in the context of nucleic acid sequences, the term "chimeric" refers to at least two connected nucleic acid sequences that are not naturally connected. Chimeric nucleic acid sequences include connected nucleic acid sequences of different natural origins. Chimeric nucleic acid sequences may also include nucleic acid sequences of the same natural origin, provided that they are not naturally connected. For example, a nucleic acid sequence constituting a promoter obtained from a specific cell type may be connected to a nucleic acid sequence encoding a polypeptide obtained from the same cell type, but is generally not connected to a nucleic acid sequence constituting a promoter. Chimeric nucleic acid sequences also include nucleic acid sequences comprising any naturally occurring nucleic acid sequence connected to any non-naturally occurring nucleic acid sequence.
[0090] Disclosed herein are novel methods for the production of recombinant insulin and / or insulin analogs or derivatives thereof in mammalian cells. The methods described herein describe specific conditions and reagent combinations that result in increased expression of recombinant insulin and / or insulin analogs as soluble proteins in host cells and do not require extraction from inclusion bodies or in vitro refolding or disulfide bond shuffling steps. One advantage conferred by the methods disclosed herein is that shorter and simplified protein extraction and purification protocols can be used due to increased yields of correctly folded and processed insulin and / or insulin analog proteins in the soluble fraction of the host cells.
[0091] Figure 1The history of insulin production is depicted, and a schematic diagram of a four-step synthesis strategy for synthesizing insulin analogs by the method of the present disclosure is further provided. Recombinant human insulin first entered human clinical trials in 1980. At that time, the A chain and B chain of the insulin molecule were produced separately in Escherichia coli and then merged by chemical techniques (Frank et al., 1981). Since 1986, different recombinant processes have been used. The human genetic coding of proinsulin including the A chain and the B chain is inserted into Saccharomyces cerevisiae (Thim et al., 1986) or Pichia pastoris (Wang et al., 2001). The connecting peptide is cleaved from the proinsulin by an enzymatic reaction to form human insulin. However, the yield of all these procedures is lower than expected and the cost is also higher than expected. The present disclosure relates to an improved procedure for producing insulin in mammalian cells. According to the present disclosure, the A chain, the B chain and the C peptide are co-expressed in a vector in a mammalian cell to enable the correct folding and secretion of insulin from the cell. The A chain and the B chain constitute the insulin molecule, and the C peptide is the connecting peptide that connects the two chains together. In the vector expression system, including proinsulin C peptide can ensure the efficient and fast reading and translation of amino acid sequence, the correct folding and stabilization of insulin molecules, the reduction of protein loss and the improvement of insulin output. When proinsulin is cleaved by protease, A chain and B chain are separated from C peptide, thereby allowing insulin to form and release. By co-expression in the same carrier or a separate carrier, add protease, such as PC1 / 3, PC2 and / or CPE in the cell, ensure successful cutting and / or pruning to produce full-function insulin. In some aspects, the vector encoding proinsulin (comprising A chain and B chain and C peptide) and proinsulin modified to one or more agents of functional insulin are introduced into mammalian cell line. In another aspect, two vectors (one encoding comprises the proinsulin of A chain and B chain and C peptide, and another encoding is modified to one or more agents of functional insulin) are introduced into mammalian cell line together. Full-function insulin is secreted by cells, and can be harvested without lysing cells.
[0092] The method of the present application has important advantages over the prior art. The insulin production cells disclosed in the present invention can continuously secrete functional insulin. The continuous secretion of fully functional insulin allows immediate capture and purification, thereby forming a closed-loop system that allows the process to be fully automated. According to an exemplary non-limiting embodiment, an integrated unit is provided, which comprises a perfusion bioreactor and a multi-column chromatography, wherein the material flows continuously throughout the process for maintaining insulin production cells and capturing secreted insulin. The bioreactor is perfused at a set rate, and its effluent is directly sent to the purification system, resulting in periodic or continuous collection of insulin within a similar or extended time frame to meet product requirements. The details of the continuous manufacturing process are described in Chiang et al. Biotechnology and Bioengineering.2019 and Lute et al. Biotechnol Progress.2020, and the contents of the documents are hereby expressly incorporated herein by reference for any purpose. The insulin production procedure disclosed in the present invention is a continuous process opposite to the intermittent production process of the prior art. Continuous manufacturing allows shortening of processing time, reducing manual intervention, adjusting output simply and quickly according to demand, and reducing equipment size by using smaller or fewer storage tanks, bioreactors and columns. For example, by using one tank instead of multiple tanks, the size of the equipment can be reduced to the size of a living room instead of a huge factory hall. This technology significantly reduces the production time of insulin from several months to 1-4 weeks.
[0093] In certain aspects, the disclosure provides recombinant nucleic acids encoding insulin analogs, expression vectors containing insulin analogs, host cells comprising variant nucleic acids and / or expression vectors, and methods for producing variant proteins.
[0094] Therefore, the present disclosure relates to processes or methods for producing insulin and / or insulin analogs in mammalian host cells that avoid expensive and time-consuming downstream purification and processing steps to provide higher yields of insulin and / or insulin analogs, thereby reducing costs to make insulin, insulin analogs and / or their derivatives cheaper.
[0095] The biosynthesis of insulin through its precursors, preproinsulin and proinsulin is one of the key processes to ensure that pancreatic beta cells produce sufficient insulin. See Steiner D., Chan, S. & Rubenstein, A. (2000) in Handbook of Physiology, The Endocrine System, edited by Jefferson, L. & Cherrington, A. (Oxford Univ. Press, New York), Volume II, pages 49-77, Goodge KA & Hutton, JC (2000) Semin. Cell. Dev. Biol. 11, 235-242. The effective conversion of proinsulin into insulin requires cleavage at the two connection points connecting the connecting fragments of the B chain and the A chain to release insulin and C peptide. These products are usually stored in mature secretory granules (accounting for >95% of the total amount of insulin-related substances), waiting to be secreted in response to glucose and other stimuli. Such as Figure 2A As shown, the initial processing cleavage occurs between residues 32 and 33 (R↓E) and residues 65 and 66 (R↓G) at the junction of the B chain and the A chain, respectively. Recognition of these sites by the neuroendocrine convertases PC1 / 3 (SPC3) and PC2 (SPC2) (Seidah NG & Chrétien, M. (1999) Brain Res. 848, 45-62, Zhou A., Webb, G., Zhu, X. & Steiner, DF (1999) J. Biol. Chem. 274, 20745-20748) involves interactions with 4-6 residues upstream and at least two residues downstream, namely in human proinsulin residues 27-34 and residues 60-67, surrounding these two sites. The C-terminal region of the B chain is surrounded by R 31 -R 32 Extended insulin and C-terminal end by K 64 -R 65 The initial cleavage product of the extended C-peptide is then trimmed by carboxypeptidase E (CPE) to remove these basic residues (L. Fricker L. (1988) Annu. Rev. Physiol. 50, 309-321. pmid: 2897826) to produce the mature β-cell secretory product. These convertases and CPEs act primarily within mature dense core particles in the regulated secretory pathway.
[0096] Figure 2BThe structures of several insulin analogs are illustrated. Insulin lispro and insulin aspart are fast-acting analogs that reduce self-association due to protein engineering. In insulin lispro, the lysine-proline (Lys-Pro) sequence at the end of the insulin B chain is reversed, thereby generating steric hindrance and reducing the ability to self-associate. Insulin aspart incorporates an amino acid change (Pro B28 becomes aspartic acid Asp), which also produces charge repulsion and steric hindrance due to local conformational changes at the carboxyl end of the B chain. Insulin glargine is a long-acting insulin containing two additional arginine molecules (Arg B31 and Arg B32) at the end of the B chain to change the isoelectric point. Glycine substitution is performed at A21 (A chain) to stabilize the molecule. Insulin detemir is another long-acting insulin containing the ε-amino acylation of Lys B29. Acylation promotes the reversible binding of insulin to albumin, thereby delaying its absorption from subcutaneous tissue and transport across the skeletal muscle capillary endothelium.
[0097] The method of making insulin in the early stage is to produce A chain and B chain by transfecting appropriate host cells with vectors encoding A chain and B chain respectively. Then the two chains are purified, then mixed together, and connected by disulfide bonds through reduction-reoxidation reaction, and then purified. The purification step is completed by chromatography or separation technology, which utilizes the difference of molecular charge, size and affinity for water. The procedures used include ion exchange columns, reverse phase high performance liquid chromatography and gel filtration chromatography columns. Alternatively, biosynthesized human insulin and its analogs are produced by conversion of single-chain fusion proteins. The methods for producing these drugs are generally described in many patent specifications and scientific publications, and are based on the overexpression of genes encoding preproinsulin, i.e., mixed polypeptides containing leader protein and proinsulin, i.e., insulin B chain (or its derivatives), connecting peptides and insulin A chain (or its derivatives). Once the fusion protein is separated, the next manufacturing step is to remove the leader protein and connecting peptide, and then separate the pure hormone.
[0098] In some aspects, the disclosure provides a method for producing recombinant functional human insulin analog or its derivatives by cultivating a host cell comprising a heterologous nucleic acid sequence of a proinsulin peptide encoding a human insulin analog and / or its derivatives or modified. In some aspects, the nucleic acid sequence of the precursor peptide encoding a human insulin analog or its derivatives also encodes one or more agents for processing the modified proinsulin or its derivatives into functional insulin analog or its derivatives. In some aspects, the precursor of a human insulin analog or its derivatives comprises the B chain of human insulin or its analogs, the A chain of human insulin or its analogs and the C peptide connecting the B chain and the A chain.
[0099] Preferred heterologous nucleic acids encode proinsulin polypeptides. In some aspects, the heterologous nucleic acid sequence encodes a modified proinsulin polypeptide having at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to the amino acid sequences shown in SEQ ID: No. 1, SEQ ID: No. 2; SEQ ID: No. 3 and SEQ ID: No. 4 (Table 2). In some aspects, the heterologous nucleic acid encodes a polypeptide having an amino acid sequence as shown below: SEQ ID: 1, SEQ ID: 2; SEQ ID: 3 and SEQ ID: No. 4. In some aspects, the modified proinsulin polypeptide comprises insulin chain A, insulin chain B and a connecting C peptide connecting chain A and chain B. In some aspects, the insulin chain A comprises a sequence that is at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to the amino acid sequence shown in SEQ ID NO: 9, 11 or 13. In some aspects, the insulin B chain comprises a sequence that is at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to the amino acid sequence shown in SEQ ID NO: 11, 13 or 15. Table 2: Proinsulin polypeptide constructs of insulin analogs Note: The signal peptide sequence is underlined; the B chain sequence is in bold; the C peptide sequence is in italics; and the A chain sequence is in bold and italics.
[0100] In some aspects, one or more agents for processing modified proinsulin into functional insulin analogs or derivatives thereof include one or more endoproteases and carboxypeptidase E. In some aspects, the endoproteases include prohormone convertase 1 / 3 (PC1 / 3) and prohormone convertase 2 (PC2). The carboxypeptidase can be any carboxypeptidase that can effectively remove the C-terminal extension of the B chain. A very suitable enzyme is carboxypeptidase Y enzyme (CPY) or a mutant thereof. In some aspects, a mammalian host cell is modified to express one or more agents for processing modified proinsulin into functional insulin analogs or derivatives thereof. In some aspects, one or more agents have at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity with the amino acid sequences shown in SEQ ID: No.5, SEQ ID: No.6; SEQ ID: No.7 and SEQ ID: No.8. In certain aspects, the one or more agents have an amino acid sequence as shown in SEQ ID: No.5, SEQ ID: No.6; SEQ ID: No.7 and SEQ ID: No.8. Table 3: Agents used to process proinsulin into mature insulin Note: Signal peptide sequences are underlined; propeptide sequences are italicized; protease sequences are bold; active site residues are bold and underlined.
[0101] According to the present disclosure, nucleic acids encoding insulin analogs of interest will be isolated, cloned and usually altered using recombinant methods. Such aspects are used, including but not limited to, in protein expression or in the process of generating variants, derivatives, expression cassettes or other sequences derived from insulin polypeptides.
[0102] In some aspects, the sequence encoding the polypeptide of the present invention is operably linked to a heterologous promoter, such as a strong constitutive promoter. Strong constitutive promoters that drive expression in many mammalian cell types include, but are not limited to, adenovirus major late promoter, human cytomegalovirus immediate early promoter, SV40 and Rous sarcoma virus promoter, and mouse 3-phosphoglycerate kinase promoter EF1α.
[0103] The nucleic acid sequence encoding insulin analogs or derivatives thereof that can be used according to the methods and compositions provided herein can be any nucleic acid sequence encoding insulin analog polypeptides, including any proinsulin and preproinsulin and / or their corresponding analog forms. In some aspects, the nucleic acid can contain one or more substitutions, additions, deletions or insertions. Due to the redundancy of the genetic code, nucleic acid variants may or may not affect the amino acid sequence. Exemplary nucleic acid sequences encoding insulin analogs, proinsulin and preproinsulin and / or their corresponding analog forms are well known in the art, and generally can be easily obtained from various mammalian sources including humans (Bell, GI et al., 1980, Nature 284:26-32). Alternative methods can be used to separate additional nucleic acid sequences encoding insulin polypeptides, and new sequences can be found and used according to the disclosure. In a preferred aspect, the nucleic acid sequence encoding insulin analogs or derivatives thereof is human insulin. The nucleic acid sequence encoding insulin analogs and / or insulin precursor analogs or derivatives thereof can be of genomic or cDNA origin, for example, by preparing a genomic or cDNA library and screening for nucleic acid sequences encoding all or part of a polypeptide using synthetic oligonucleotide probe hybridization according to standard techniques (see, for example, Sambrook, J, Fritsch, EF and Maniatis, T, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1989). Nucleic acid sequences encoding insulin analogs and / or insulin analog precursors or derivatives thereof can also be prepared synthetically by established standard methods, such as the phosphoramidite method described by Beaucage and Caruthers, Tetrahedron Letters 22 (1981), 1859-1869, or by the method described by Matthes et al., EMBO Journal 3 (1984), 801-805. Nucleic acid sequences can also be prepared by polymerase chain reaction using specific primers, for example as described in US Pat. No. 4,683,202 or Saiki et al., Science 239 (1988), 487-491.
[0104] Nucleotide sequences encoding insulin analogs comprising non-naturally encoded amino acids can be synthesized based on the amino acid sequence of the parent polypeptide, including but not limited to having the amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO.: 4, and then the nucleotide sequence is changed to achieve the introduction (i.e., incorporation or substitution) or removal (i.e., deletion or substitution) of the relevant amino acid residues. The nucleotide sequence can be conveniently modified by site-directed mutagenesis according to conventional methods. Alternatively, the nucleotide sequence can be prepared by chemical synthesis, including but not limited to by using an oligonucleotide synthesizer, wherein the oligonucleotide is designed based on the amino acid sequence of the desired polypeptide, and preferably those codons that are favorable in the host cell of the recombinant polypeptide to be produced are selected.
[0105] Many insulin analogs known in the prior art (see, for example, U.S. Patent Nos. 5,461,031; 5,474,978; 5,164,366 and 5,008,241) and can be used according to the disclosure. Analogs that can be used herein include human insulin molecules, in which the amino acid residue 28 (B28) of the B chain has been changed to aspartic acid, lysine or isoleucine from its natural proline residue. In some aspects, the lysine residue at B29 is modified to proline. In addition, the asparagine at A21 can be changed to alanine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, methionine, serine, threonine, tryptophan, tyrosine or valine. Other examples of insulin analogs that can be used herein include: human insulin lacking the B30 residue, also often referred to as "desB30" or "B(1-29)"; insulin "B(1-27)" lacking the last three amino acid residues; insulin molecules lacking the phenylalanine residue at B1; and analogs in which the A chain or the B chain has an N-terminal or C-terminal extension, for example, the B chain can be N-terminally extended by the addition of two arginine residues. The present disclosure utilizes conventional techniques in the field of recombinant genetics. Basic texts that disclose general methods of use in the present invention include Sambrook et al., Molecular Cloning, A Laboratory Manual (3rd Edition 2001); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., ed., 1994)).
[0106] General texts describing molecular biology techniques include Berger and Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology Vol. 152 Academic Press, Inc., San Diego, Calif. (Berger); Sambrook et al., Molecular Cloning A Laboratory Manual (2nd ed.), Vols. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989 ("Sambrook") and Current Protocols in Molecular Biology, FM Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (supplemented through 1999) ("Ausubel"). These texts describe mutagenesis, the use of vectors, promoters, and many other related topics, including, but not limited to, the generation of genes or polynucleotides including selector codons for the production of proteins including unnatural amino acids, orthogonal tRNAs, orthogonal synthetases, and pairs thereof.
[0107] As discussed herein, "operating elements" include at least one promoter, at least one operator, at least one leader sequence, at least one Shine-Dalgarno sequence, at least one termination codon, and any other DNA sequence necessary or preferred for the appropriate transcription and subsequent translation of the vector DNA. Specifically, it is expected that such vectors will contain at least one replication origin recognized by the host microorganism and at least one selectable marker and at least one promoter sequence that can cause transcription of the synthetic DNA sequence. It is also preferred that, in one aspect, the vector contains certain DNA sequences that can serve as the function of a regulator, and other DNA sequences that can encode regulatory proteins. In one aspect, these regulators are used to prevent the expression of a DNA sequence in the presence of certain environmental conditions, and in the presence of other environmental conditions, allow transcription and subsequent expression of the protein encoded by the DNA sequence.
[0108] Accordingly, a nucleic acid sequence encoding at least one insulin analog or derivative thereof is linked to a promoter capable of controlling the expression of an insulin polypeptide in a mammalian host cell. Alternatively, a nucleic acid sequence encoding an insulin analog or derivative thereof and further encoding one or more agents for processing modified proinsulin into functional insulin analogs or derivatives thereof is linked to a promoter capable of controlling the expression of an insulin polypeptide in a mammalian host cell.
[0109] The promoter can be any DNA sequence that exhibits transcriptional activity in the selected host cell and can be derived from a gene encoding a protein that is homologous or heterologous to the host cell, and includes mutations, truncations, and hybrid promoters. The promoter can be obtained from a gene encoding an extracellular polypeptide or an intracellular polypeptide that is homologous or heterologous to the host cell. Therefore, the disclosure also provides a chimeric nucleic acid sequence encoding an insulin analog or a derivative thereof, which is connected to a promoter that can control expression in a mammalian host cell. The promoter that can be used herein is generally recognized in the art, including any promoter that can control the expression of polypeptides in mammalian cells. Certain genetic elements that can enhance the expression of insulin analog polypeptides or derivatives thereof can be used herein.
[0110] In some aspects, the chimeric nucleic acid sequence can be incorporated into the recombinant expression vector to ensure good expression in mammalian cells. The chimeric nucleic acid sequence comprises a promoter capable of controlling expression in mammalian host cells, the promoter being connected to a nucleic acid sequence encoding an insulin analog polypeptide or derivatives thereof, and the nucleic acid sequence encoding is used to process the modified proinsulin into one or more agents of functional insulin analogs or derivatives thereof. In some aspects, the chimeric nucleic acid sequence can be incorporated into the recombinant expression vector to ensure good expression in mammalian cells. The chimeric nucleic acid sequence comprises a promoter capable of controlling expression in mammalian host cells, the promoter being connected to a nucleic acid sequence encoding an insulin analog polypeptide or derivatives thereof and further encoding is used to process the modified proinsulin into one or more agents of functional insulin analogs or derivatives thereof.
[0111] In some aspects, the recombinant expression vector according to the present disclosure comprises a nucleic acid sequence encoding a cleavable linker, which connects the proinsulin polypeptide and an agent for processing proinsulin into a functional insulin analog or derivative thereof. A cleavable linker can be a part of a peptide, polypeptide or polypeptide, which is cleaved after the protein or polypeptide is produced. Specifically, a cleavable linker is a self-cleavable, self-cleaving, self-cleavage peptide or linker, and these terms are used interchangeably herein. In one aspect, a cleavable linker comprises a 2A peptide. "2A" or "2A-like" sequences are part of a large family of peptides that can cause peptide bond skipping. Specifically, it has recently been discovered that the "self-cleavage" mechanism mediated by 2A is that the ribosome skips the formation of the glycyl-prolyl peptide bond at the C-terminus of the 2A peptide. The cleavage mediated by the 2A peptide begins after translation. Successful skipping and restarting of translation results in two "cleaved" proteins: a protein upstream of 2A with the complete 2A peptide attached except for the C-terminal proline, and a protein downstream of 2A with one proline attached to the N-terminus. Several 2A peptides have been found in picornaviruses, insect viruses, and type C rotaviruses. Examples of cleavable linkers according to the present disclosure include, but are not limited to, porcine teschovirus-1 2A (P2A), FMDV 2A (F2A); equine rhinitis virus A (ERAV) 2A (E2A); and sphenobarbital moth virus 2A (T2A), cytoplasmic polyhedrosis virus 2A (BmCPV2A), and malarial disease virus 2A (BmIFV2A), or combinations thereof, such as described in Kim et al. (2011) PLoS ONE and in Liu et al. (2017) Sci Rep. 2017.
[0112] The selection and construction of expression vectors comprising heterologous nucleic acid sequences disclosed herein and suitable for mammalian host cells are known in the art. Expression vectors typically contain a plasmid origin of DNA replication, a selectable marker (e.g., an antibiotic selection marker or eGFP), and a promoter and a transcription terminator separated by a DNA sequence encoding at least one ribosome binding site (expression cassette). Transcription of heterologous nucleic acids (target genes, such as nucleic acid sequences encoding insulin analog polypeptides or derivatives thereof) is typically controlled by regulated promoters, which allows cell growth to be separated from product synthesis, thereby resulting in a higher yield than protein constitutive expression.
[0113] The recombinant expression system is selected from a eukaryotic host. In some aspects, the eukaryotic host includes a mammalian cell. Commercial sources of mammalian cells for recombinant protein expression also provide instructions for cell use. The selection of the expression system depends on the desired characteristics of the expressed polypeptide.
[0114] As used herein, the term "recombinant" describing a protein or polypeptide refers to a polypeptide produced by expression of a recombinant polynucleotide. As used herein, the term "recombinant" refers to a cell, a cell that can or has been used as a recipient of a recombinant vector or other transfer DNA, including the descendants of the original cell that has been transfected. It should be understood that due to accidental or deliberate mutations, the descendants of a single parent cell will not be completely identical to the original parent in morphology, genome, or total DNA complement. The descendants of parent cells that are sufficiently similar to the parent to have relevant characteristics (such as the presence of a nucleotide sequence encoding a desired polypeptide) are also considered descendants.
[0115] Thus, the present disclosure includes a recombinant expression vector comprising as operably linked components in the 5' to 3' transcriptional orientation: (i) a nucleic acid sequence capable of controlling expression in a mammalian cell; and (ii) a nucleic acid sequence encoding a proinsulin polypeptide or a derivative thereof; wherein the expression vector is suitable for expression in a mammalian host cell. Thus, the present disclosure also encompasses a recombinant expression vector comprising as operably linked components in the 5' to 3' transcriptional orientation: (i) a nucleic acid sequence capable of controlling expression in a mammalian host cell; (ii) a nucleic acid sequence encoding at least one proinsulin polypeptide or a derivative thereof; and (iii) a nucleic acid sequence encoding one or more agents for processing the modified proinsulin into a functional insulin analog or a derivative thereof, wherein the expression vector is suitable for expression in a mammalian host cell.
[0116] In order to guide insulin analogs or derivatives thereof into the secretory pathway of the host cell, a secretion signal sequence (also referred to as a leader sequence, pre-pro sequence or pre-sequence) can be provided in the expression vector. The secretion signal sequence is connected to the DNA sequence encoding proinsulin in the correct reading frame. The secretion signal sequence is usually located at the 5' of the DNA sequence encoding the peptide. The signal peptide can be a naturally occurring signal peptide, or a functional part thereof, or a synthetic peptide. Therefore, in some aspects, the expression vector of the present invention is also included in the nucleic acid sequence encoding the signal peptide at the N-terminus of the nucleic acid sequence encoding the proinsulin polypeptide. The signal peptide of the present invention allows cells to secrete insulin molecules and is removed from the mature molecule during the secretion process. Table 4 lists some commonly used signal peptide sequences for the effective secretion of recombinant proteins expressed in mammalian cells. Table 4 Exemplary signal peptides Leading sequence name sequence SEQ ID NO People OSM MGVLLTQRTLLSLVLALLFPSMASM 16 VSV-G MKCLLYLAFLFIGVNC 17 Mouse lgκ METDTLLLWVLLLWVPGSTGD 18 Mouse Ig heavy chain MGWSCIILFLVATATGVHS 19 BM40 MRAWIFFLLCLAGRALA 20 Secrecon MWWRLWWLLLLLLLLWPMVWA 21 Human lgKVIII MDMRVPAQLLGLLLLWLRGARC 22 CD33 MPLLLLLPLLWAGALA 23 tPA MDAMKRGLCCVLLLCGAVFVSPS 24 Human chymotrypsinogen MAFLWLLSCWALLGTTFG 25 Human trypsin-2 zymogen MNLLLILTFVAAAVA 26 Human IL-2 MYRMQLLSCIALSLALVTNS 27 Gaussia luc MGVKVLFALICIAVAEA 28 Albumin (HSA) MKWVTFISLLFSSAYS 29 Influenza hemagglutinin MKTIIALSYIFCLVLG 30 Human insulin MALWMRLLPLLALLALWGPDPAAA 31 Silk protein LC MKPIFLVLLVVTSAYA 32
[0117] In some aspects, the expression vector of the present disclosure also includes a nucleic acid sequence encoding an N-terminal fusion partner connected to the polypeptide in the 5' to 3' transcription direction to produce a fusion protein. In some aspects, the fusion partner exists during translation, but is cleaved by an intracellular protease (such as furin) during protein export, thereby releasing the target polypeptide. Non-limiting examples of N-terminal fusion partners include human ferritin (SCN), mouse ferritin, chicken Ex-FABP or quail Q83. SCN fusion promotes enhanced protein folding and rapid protein expression. The details of producing SCN fusion proteins are described in US10,156,559, the contents of which are hereby expressly incorporated herein by reference in their entirety for any purpose.
[0118] Thus, in some aspects, the present disclosure provides an expression vector comprising as operably linked components in the 5' to 3' transcriptional direction: (i) a nucleic acid sequence capable of controlling expression in a mammalian host cell; (ii) a nucleic acid sequence encoding a signal peptide for effective secretion of an insulin analog or derivative thereof; (iii) optionally, a nucleic acid sequence encoding an N-terminal fusion ligand; (iv) a nucleic acid sequence encoding a modified proinsulin polypeptide; and (v) a nucleic acid sequence encoding one or more agents for processing the modified proinsulin into a functional insulin analog or derivative thereof. In some aspects, the agent for processing the modified proinsulin into a functional insulin analog or derivative thereof is selected from the group comprising prohormone convertase 1 / 3 (PC1 / 3), PC2, and carboxypeptidase E (CPE). In some aspects, the agent for processing the modified proinsulin into a functional lispro insulin or a derivative thereof comprises PC1 / 3, CPE, and optionally PC2. In another aspect, the agent for processing the modified proinsulin into a functional glargine insulin or a derivative thereof comprises PC1 / 3 and optionally PC2.
[0119] In some aspects, the present disclosure provides a first expression vector and a second expression vector. In some aspects, the first expression vector comprises as an operably connected component in the 5' to 3' transcriptional direction: (i) a nucleic acid sequence capable of controlling expression in mammalian cells; (ii) a nucleic acid sequence encoding a signal peptide for effectively secreting an insulin analog or its derivative; (iii) optionally, a nucleic acid sequence encoding an N-terminal fusion ligand; and (iv) a nucleic acid sequence encoding a modified proinsulin polypeptide. In another aspect, the second expression vector comprises as an operably connected component in the 5' to 3' transcriptional direction: (i) a nucleic acid sequence capable of controlling expression in mammalian cells; and (ii) a nucleic acid sequence encoding one or more agents for processing the modified proinsulin into a functional insulin analog or its derivative. In some aspects, the agent for processing the modified proinsulin into a functional insulin analog or its derivative is selected from the group comprising PC1 / 3, PC2 and CPE. In some aspects, the agent for processing the modified proinsulin into a functional insulin lispro or its derivative comprises PC1 / 3, CPE and optional PC2. In another aspect, the agent for processing modified proinsulin into functional insulin glargine or a derivative thereof comprises PC1 / 3 and optionally PC2.
[0120] In some aspects, the present disclosure provides a method for making insulin analogs and / or derivatives thereof, comprising producing a competent mammalian host cell that expresses and secretes insulin, comprising transforming the host cell with an expression vector that co-expresses a modified proinsulin polypeptide and one or more agents for processing the modified proinsulin into a functional insulin analog or derivative thereof. In another aspect, the present disclosure provides a method for making insulin analogs and / or derivatives thereof, comprising producing a competent mammalian host cell that can express and secrete insulin, comprising transforming the host cell with a first expression vector that expresses a modified proinsulin polypeptide and a second expression vector that expresses one or more agents for processing the modified proinsulin into a functional insulin analog or derivative thereof.
[0121] In some aspects, the disclosure provides a method for making a fast-acting insulin analog and / or its derivatives, comprising transforming a mammalian host cell with an expression vector comprising (i) a nucleic acid sequence capable of controlling expression in a mammalian host cell; (ii) a nucleic acid sequence encoding a signal peptide for effective secretion of an insulin analog or its derivatives; (iii) optionally, a nucleic acid sequence encoding an N-terminal fusion ligand; (iv) a nucleic acid sequence encoding a modified proinsulin polypeptide; (v) a nucleic acid sequence encoding PC1 / 3; (vi) a nucleic acid sequence encoding CPE; and (vii) optionally, a nucleic acid sequence encoding PC2. In some aspects, the fast-acting insulin analog is insulin lispro.
[0122] In some aspects, the present disclosure provides a method for making a long-acting insulin analog and / or its derivatives, comprising transforming a mammalian host cell with a recombinant expression vector, wherein the recombinant expression vector comprises (i) a nucleic acid sequence capable of controlling expression in a mammalian host cell; (ii) a nucleic acid sequence encoding a signal peptide for effective secretion of an insulin analog or its derivatives; (iii) optionally, a nucleic acid sequence encoding an N-terminal fusion ligand; (iv) a nucleic acid sequence encoding a modified proinsulin polypeptide; (v) a nucleic acid sequence encoding PC1 / 3; and (vi) optionally, a nucleic acid sequence encoding PC2. In some aspects, the long-acting insulin analog is insulin glargine.
[0123] In order to produce long-acting insulin, such as glargine insulin containing two extra arginine molecules (Arg B31 and Arg B32) at the end of the B chain, it may be necessary to block endogenous carboxypeptidase E activity to maintain the arginine at both ends. Therefore, the present disclosure provides a method for manufacturing long-acting insulin analogs and / or derivatives thereof, which also includes an optional step of blocking endogenous carboxypeptidase E (CPE) activity. In some aspects, the step of blocking endogenous carboxypeptidase E activity includes introducing deletion or mutation into endogenous CPE, resulting in expression or activity reduction or elimination. In some aspects, the host cell can be a CRISPR-modified host cell with reduced or eliminated CPE activity. For example, CPE expression can be reduced or eliminated using CRISPR or such host cells can be produced by allowing catalytically inactivated CPE expression. For example, the serine at position 202 of the sequence shown in SEQ ID NO:9 can be mutated to, for example, proline. In some aspects, the reduction or elimination of CPE activity can be conditional or inducible (for example, in the form of a Cre-dependent construct). In some aspects, the step of blocking endogenous carboxypeptidase E activity includes co-expressing a mutated CPE having at least one mutation in a mammalian host cell, wherein the mutated CPE is located at a position selected from the group consisting of 72H, 75E, 147R, 192H, 202S, 243Y and 296E comprising the sequence shown in SEQ ID NO:9. In some aspects, the nucleic acid sequence encoding the mutated CPE is included in an expression vector for the co-expressed modified proinsulin polypeptide. In another aspect, the nucleic acid sequence encoding the mutated CPE is included in a separate expression vector. In some aspects, the present disclosure provides a host cell expressing a catalytically inactive CPE, wherein the CPE binds to a substrate but does not cleave a peptide bond, wherein the catalytically inactive CPE is located at a position selected from the group consisting of 72H, 75E, 147R, 192H, 202S, 243Y and 296E comprising the sequence shown in SEQ ID NO:9 and has at least one mutation. In some aspects, the step of blocking endogenous CPE activity comprises adding a blocking agent selected from the group consisting of dopamine quinine, dopamine, norepinephrine, epinephrine, potato carboxypeptidase inhibitor (PCI), a 9-mer peptide designated CPI-2KR, and a peptide encoding a decoy arginine sequence. The decoy arginine peptide of the present disclosure comprises a polymer of 3 amino acids in length, and has an amino acid sequence having at least 70% amino acid sequence identity with an extension of the C-terminus of the long-acting insulin B chain, such as the sequence shown in SEQ ID NO: 15. The decoy arginine peptide is configured to mimic the extension of the C-terminus of the long-acting insulin B chain to bind to endogenous CPE, so that it prevents endogenous CPE from removing the extension of the C-terminus of the B chain.
[0124] In some aspects, the disclosure provides a CPE of mutation or a polynucleotide encoding a CPE of mutation, wherein the CPE of mutation is catalytically inactive. In some aspects, the CPE of mutation binds to proteins but does not hydrolyze proteins. In some aspects, the CPE of mutation comprises at least one mutation at a position selected from the group of 72H, 75E, 147R, 192H, 202S, 243Y and 296E of a sequence comprising SEQ ID NO:9.
[0125] The term "suitable for expression in a mammalian host cell" means that the recombinant expression vector comprises a chimeric nucleic acid sequence of the present disclosure linked to the genetic elements required to achieve expression in a mammalian cell. Expression of recombinant proteins outside of their original host is generally difficult. For example, changes in codon usage bias have been observed in different species of bacteria (Sharp et al., 2005, Nucl. Acids. Res. 33: 1141-1153). Even overexpression of recombinant proteins in their natural hosts can be difficult. In certain aspects of the present invention, the nucleic acid to be introduced into the host cell can be codon optimized to enhance protein expression. Codon optimization refers to changing the codons of a gene or nucleic acid coding region in order to transform an organism to reflect the typical codon usage of the host organism without changing the polypeptide encoded by the DNA.
[0126] In this respect, the genetic elements that can be included in the expression vector include transcription termination regions, polyadenylation signals and translation enhancer sequences, one or more nucleic acid sequences encoding marker genes, one or more replication origins, etc. In some aspects, the recombinant expression vector can also include a DNA sequence that enables the vector to replicate in a mammalian host cell. In some aspects, the expression vector also includes the genetic elements required for the integration of the vector or its portion into the nuclear genome of the mammalian host cell.
[0127] The recombinant vector can be an autonomously replicating vector, i.e., a vector existing as an extrachromosomal entity, whose replication is independent of the replication of the chromosome, such as a plasmid, an extrachromosomal element, a minichromosome or an artificial chromosome. The vector can contain any means for ensuring self-replication. Alternatively, when introduced into a host cell, the vector can be a vector that is integrated into the genome and replicated together with the chromosome into which it is integrated. In addition, a single vector or plasmid, or two or more vectors or plasmids (which together contain the total DNA to be introduced into the host cell genome), or a transposon can be used. The vector can be a linear or closed circular plasmid, and preferably contains elements that allow the vector to be stably integrated into the host cell genome or allow the vector to replicate autonomously in the cell independently of the genome. In some aspects, the recombinant expression vector can replicate in a mammalian host cell. Recombinant vectors suitable for introducing nucleic acid sequences into host cells include mammalian expression systems, such as lentiviral-based vectors, pHEK293 Ultra expression vectors and pEF1α-IRES.
[0128] The host cell is genetically engineered (including but not limited to conversion, transduction or transfection) with the polynucleotide of the present disclosure or the construct including the polynucleotide of the present disclosure, including but not limited to the vector of the present disclosure, which can be, for example, a cloning vector or an expression vector. For example, the coding region of the orthogonal tRNA, orthogonal tRNA synthetase and the protein to be derived is operably connected to the gene expression control element that functions in the desired host cell. The vector can be, for example, in the form of a plasmid, a cosmid, a phage, a bacterium, a virus, a naked polynucleotide or a conjugated polynucleotide. The vector is introduced into cells and / or microorganisms by standard methods, including electroporation (Fromm et al., Proc. Natl. Acad. Sci. USA 82, 5824 (1985)), viral vector infection, small particles with nucleic acid in the matrix of beads or particles or on the surface of high-speed ballistic penetration (Klein et al., Nature 327, 70-73 (1987)) and / or similar methods. Techniques suitable for transferring nucleic acids into cells in vitro include the use of liposomes, microinjection, cell fusion, DEAE-dextran, calcium phosphate precipitation, and the like. In vivo gene transfer techniques include, but are not limited to, transfection with viral (usually retroviral) vectors and viral coat protein-liposome mediated transfection [Dzau et al., Trends in Biotechnology 11: 205-210 (1993)]. In some cases, it may be necessary to provide a target cell targeting agent for the nucleic acid source, such as antibodies specific to cell surface membrane proteins or target cells, ligands for receptors on target cells, and the like. In the case of using liposomes, proteins that bind to cell surface membrane proteins associated with endocytosis can be used for targeting and / or promoting uptake, such as capsid proteins or fragments thereof for specific cell types, antibodies to proteins that are internalized in the circulation, and proteins that target intracellular localization and enhance intracellular half-life.
[0129] In some aspects, the host cell provided in the method disclosed herein is a mammalian host cell. The mammalian host cell into which the nucleic acid sequence and / or the recombinant expression vector are introduced can be any mammalian cell capable of expressing insulin precursors and / or insulin analogs, including but not limited to HEK293, CHO, COS and HeLa cells. The disclosure also provides a host cell selected from algae and yeast. The host cell provided in the method disclosed herein can include a genetic modification to allow stable disulfide bonds to be formed in the cytoplasm.
[0130] The recombinant expression vector, nucleic acid sequence and chimeric nucleic acid and sequence of the present invention can be prepared according to methods well known to those skilled in the art of molecular biology. It is well known to those skilled in the art (for example, referring to Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY, 1989) to connect the DNA sequence encoding insulin product, optionally encode the sequence for processing modified proinsulin into one or more agents of functional insulin analogs or derivatives thereof, and optionally terminator and / or secretion signal sequence, and insert them into the program in the suitable carrier containing the information required for replication respectively. Such preparation is generally related to but not limited to the bacterial species Escherichia coli as the intermediate cloning host. The preparation of Escherichia coli (E.coli) vector and mammalian transformation vector can be completed using commonly known techniques, such as restriction digestion, connection, gel electrophoresis, DNA sequencing, polymerase chain reaction (PCR) and other methods. These methods allow the connection of nucleic acid sequences and polypeptides involved in the present disclosure. There are a variety of cloning vectors that can be used to implement the necessary steps required for preparing the recombinant expression vector. In some aspects, the method includes infusion cloning. Infusion cloning is a highly efficient, ligation-independent cloning method based on annealing of complementary ends of the cloned insert and the linearized cloning vector. This method enables easy single-step directional cloning of any gene of interest into any vector at any locus. Infusion constructs are seamless, allowing for continuity of the translational reading frame without any interfering "scar" sequences.
[0131] Typically, these cloning vectors contain markers that allow selection of transformed cells. Nucleic acid sequences can be introduced into these vectors, which are then introduced into E. coli grown in appropriate culture media. After harvesting and lysing the cells, the recombinant expression vector can be easily recovered from the cells. In addition, general guidance on the preparation of recombinant vectors can be found in, for example: Sambrook et al., Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989, Vol. 3.
[0132] According to the present disclosure, spendable marker genes include all genes that allow to distinguish transformed cells from non-transformed cells, including all selectable and screenable marker genes.The marker gene can be a resistance marker, such as for example kanamycin (kanamycin), ampicillin (ampicillin), G418, bleomycin (bleomycin), hygromycin (hygromycin) antibiotic resistance markers, which allow to pass through chemical means or for the tolerance or resistance marker selection traits of chemical agents.When the resistance marker is connected closely to the nucleotide sequence dosage of the coding insulin polypeptide, the resistance marker can be used for maintaining selection pressure for the plant cell or the plant group of the nucleotide sequence of the coding insulin analog polypeptide or its derivatives as yet.The screenable marker that can be used for identifying transformants by visual inspection includes 3-glucuronidase (GUS) and green fluorescent protein (GFP and eGFP).
[0133] It should be understood that the vector can be constructed by first preparing a DNA construct containing the complete DNA sequence encoding the insulin precursor of the present disclosure, optionally used to process the modified proinsulin into one or more agents of functional insulin analogs or derivatives thereof; then inserting this fragment into a suitable expression vector, or sequentially inserting DNA fragments containing the genetic information of individual elements (such as signal, propeptide, modified C-peptide, A chain and B chain, optionally used to process proinsulin into functional insulin analogs or derivatives thereof), followed by ligation.
[0134] After selecting the host organism, the vector is transferred into the host organism using methods generally known to those of ordinary skill in the art. Examples of such methods can be found in Advanced Bacterial Genetics, Cold Spring Harbor Press, Cold Spring Harbor, NY, (1980) by RW Davis et al., which is specifically incorporated herein by reference. In one aspect, it is preferred that transformation occurs at low temperatures, and temperature regulation is considered as a means of regulating gene expression by using operating elements as shown above.
[0135] The engineered host cells can be cultured in conventional nutrient media modified as appropriate for such activities as screening steps, activating promoters or selecting transformants, etc. These cells can optionally be cultured into transgenic organisms. For cell isolation and culture (e.g., for subsequent nucleic acid isolation), other useful references include, but are not limited to, Freshney (1994) Culture of Animal Cells, a Manual of Basic Technique, 3rd Edition, Wiley-Liss, New York and references cited therein; Payne et al. (1992) Plant Cell and Tissue Culture in Liquid Systems John Wiley & Sons, Inc. New York, NY; Gamborg and Phillips (eds.) (1995) Plant Cell, Tissue and Organ Culture; Fundamental Methods Springer Lab Manual, Springer-Verlag (Berlin Heidelberg New York) and Atlas and Parks (eds.) The Handbook of Microbiological Media (1993) CRC Press, Boca Raton, Fla. Mammalian host cells are cultured under conditions suitable for expression of recombinant insulin analogs and / or derivatives thereof. These conditions are generally specific for the host organism and can be readily determined by one of ordinary skill in the art from published literature on growth conditions for such organisms, such as Bergey's Manual of Determinative Bacteriology, 8th Edition, Williams & Wilkins Company, Baltimore, Md., which is specifically incorporated herein by reference.
[0136] Examples of suitable mammalian host cells are known to those of ordinary skill in the art. Such host cells can be Chinese hamster ovary (CHO) cells, (e.g., CHO-K1; ATCC CCL-61), green monkey cells (COS) (e.g., COS1 (ATCC CRL-1650), COS 7 (ATCC CRL-1651)); mouse cells (e.g., NS / O), baby hamster kidney fibroblast (BHK) cell lines (e.g., ATCC CRL-1632 or ATCC CCL-10) and human cells (e.g., HEK 293 (ATCC CRL-1573)). These cell lines and other cell lines are available from public depositories, such as American Type Culture Collection, Rockville, Md. In order to provide improved glycosylation of insulin polypeptides, mammalian host cells can be modified to express sialyltransferases, such as 2,6-sialyltransferases, such as described in U.S. Pat. No. 5,047,335, which is incorporated herein by reference.
[0137] In some aspects, the disclosure provides recombinant mammalian cells comprising polynucleotide sequences encoding required insulin analogs and / or derivatives thereof. In some aspects, the polynucleotide sequences also encode at least one agent for processing modified proinsulin into functional insulin. An expression vector comprising such polynucleotide sequences is introduced into a host cell so that the vector is maintained as a chromosomal integrant or a self-replicating extrachromosomal vector.
[0138] In some aspects, the method further comprises culturing a mammalian host cell transformed with a recombinant vector of the present invention under conditions suitable for expression of the recombinant vector of the transfection. The recombinant product expressed is then isolated, purified or recovered from the culture fluid. In some aspects, the method disclosed herein further comprises purifying the expression product recovered from the culture fluid.
[0139] In some aspects, the step of purifying the recovered expression product comprises placing the recovered expression product in a reverse phase HPLC column and eluting the sample containing the insulin analog and / or derivative thereof with an organic solvent under conditions that allow the compound to bind to the resin, and then washing the organic solvent from the resin with a buffered aqueous solution. Effective implementation of the present invention requires a personalized correct combination of the chromatographic matrix used, the pH value and the ionic strength of the buffer to achieve effective purification
[0140] Producing a large amount of mature insulin or insulin analogs in mammalian cells will significantly reduce the number of downstream purification steps necessary for producing insulin or insulin analog products with a purity high enough for pharmaceutical purposes. U.S. Patent No. 4,916,212 discloses a method for making insulin in yeast cells, wherein an insulin precursor is converted into human insulin in two steps, i.e., a single-chain insulin precursor B (1-29) -Ala-Ala-Lys-A (1-21) is converted into human insulin ester by a transpeptidation reaction, and then the insulin ester is hydrolyzed into human insulin. Each conversion step requires an initial separation step and at least one subsequent purification step. Therefore, the production of mature insulin requires at least six additional steps, including at least one enzymatic conversion.
[0141] No enzymatic cleavage is able to achieve 100% cleavage, thereby leaving uncleaved or partially cleaved impurities that must be effectively removed in the drug product. Therefore, each cleavage step will be followed by at least one separation or purification step, usually chromatographic purification by exchange chromatography, gel filtration chromatography, affinity chromatography, etc.
[0142] Protein expression can also use small-scale or large-scale fermentation methods, including but not limited to fermenters, shake flasks, fluidized bed bioreactors, hollow fiber bioreactors, roller bottle culture systems, stirred tank bioreactor systems. Each method can be carried out in batch, fed-batch or continuous mode processes.
[0143] Human insulin polypeptides of the present invention can generally be recovered using standard methods in this area. For example, the culture medium can be centrifuged and / or filtered to remove cell debris. The supernatant can be concentrated or diluted to the required volume or filtered into a suitable buffer to adjust the further purified preparation. The further purification of insulin polypeptides of the present invention comprises separating the deamidated form and the truncated form of the insulin polypeptide variant from the complete form.
[0144] Any of the following exemplary procedures may be used to purify an insulin polypeptide of the invention: affinity chromatography; anion or cation exchange chromatography (using, but not limited to, DEAE SEPHAROSE); silica chromatography; high performance liquid chromatography (HPLC); reverse phase HPLC; gel filtration (using, but not limited to, SEPHADEX G-75); hydrophobic interaction chromatography; size exclusion chromatography; metal chelate chromatography; ultrafiltration / diafiltration; ethanol precipitation; ammonium sulfate precipitation; chromatofocusing; displacement chromatography; electrophoretic procedures (including, but not limited to, preparative isoelectric focusing), differential solubility (including, but not limited to, ammonium sulfate precipitation), SDS-PAGE, or extraction.
[0145] Chromatographic column materials used for commercial scale are very expensive, so reducing the number of such chromatographic steps has a significant impact on production economics. The reduction of downstream conversion and purification steps will also reduce the labor workload and time spent in the process, thereby further improving production economics. Advantageously, the methods and compositions of the present disclosure provide the ability to produce, harvest and purify mature functional insulin or its analogs directly from culture fluid in high yield, thereby requiring fewer downstream process steps to produce products with sufficient purity for pharmaceutical use.
[0146] In some aspects, the present disclosure relates to methods for obtaining purified biologically active heterologous recombinant proteins expressed in mammalian expression systems. In some aspects, the method comprises culturing a host cell transformed by at least one vector comprising a heterologous nucleic acid sequence encoding a peptide having at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher) identity with the amino acid sequence shown in SEQ ID: No. 1, SEQ ID: No. 2; SEQ ID: No. 3 and SEQ ID: No. 4; in some aspects, the method comprises culturing a host cell transformed by at least one vector comprising a nucleotide sequence encoding a peptide having an amino acid sequence as shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID: No. 4. In some aspects, the vector comprising the heterologous nucleic acid encoding the peptide also encodes an agent for processing the heterologous protein into a mature functional protein.
[0147] In certain aspect, described method also comprises the heterologous protein of reclaiming expression, and wherein the step of reclaiming protein comprises the protein preparation of reclaiming with production from host cell separation protein.In some aspects, described method also comprises the protein preparation of reclaiming by contacting the protein preparation of reclaiming with chromatographic matrix to purify to remove at least one related impurity.Purify by applying polar organic buffer solvent and precipitating the protein of wash-out in the aqueous phase containing organic acid buffer.In any aspect of the present disclosure, mature functional protein is human insulin analog and / or its derivative.
[0148] According to one aspect of the present disclosure, the yield of purified insulin analogs and / or derivatives thereof is 75%-100%. According to another aspect of the present disclosure, the yield of purified insulin analogs and / or derivatives thereof is 75%-80%, 80%-85%, 85%-90%, 90%-95% or 95%-100%.
[0149] In certain aspects, the present disclosure provides an integrated and continuous process for manufacturing recombinant human insulin analogs and / or derivatives thereof, the process comprising: (i) culturing mammalian cells that secrete recombinant human insulin analogs in a perfusion bioreactor containing a liquid culture medium under conditions that allow the cells to secrete the recombinant insulin analogs and / or derivatives thereof into the culture medium, and wherein a substantially cell-free volume of culture medium is continuously or periodically removed from the perfusion bioreactor and fed to a first periodic countercurrent chromatography system (PCCS1); (ii) capturing the recombinant insulin analogs and / or derivatives thereof from the culture medium using the PCCS1; derivatives, wherein the PCCS1 eluate containing recombinant insulin analogs and / or derivatives thereof is continuously fed to a second periodic countercurrent chromatography system (PCCS2); and (iii) using PCCS2 to purify recombinant insulin analogs and / or derivatives thereof, wherein the purification is performed using a resin in PCCS2 having a chemical structure different from that of the resin in PCCS2 used for polishing, and the eluate from PCCS2 is insulin analogs and / or derivatives thereof; and wherein the process is integrated and runs continuously from the culturing step to the eluate from PCCS2 being insulin analogs and / or derivatives thereof. In some aspects, the mammalian cells secreting recombinant human insulin analogs are transformed with at least one vector comprising a heterologous nucleic acid sequence encoding a peptide having at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher) identity with the amino acid sequence shown in SEQ ID: No. 1, SEQ ID: No. 2; SEQ ID: No. 3 and SEQ ID: No. 4. In some aspects, the mammalian cells secreting recombinant human insulin analogs are transformed with at least one vector comprising a heterologous nucleic acid sequence encoding a peptide comprising the amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID: No. 4. In a certain aspect, at least one vector comprising a heterologous nucleic acid sequence also encodes at least one agent for processing the modified proinsulin into functional insulin. In an alternative aspect, the mammalian cell secreting the recombinant human insulin analog is further transformed with a second vector comprising a heterologous nucleic acid sequence encoding at least one agent for processing the modified proinsulin into functional insulin.In some aspects, at least one agent encoded by a heterologous nucleic acid sequence has at least about 85% (i.e., at least about 85%, 86%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to the amino acid sequence shown in SEQ ID: No. 5, SEQ ID: No. 6; SEQ ID: No. 7 and SEQ ID: No. 8. In certain aspects, at least one agent encoded by a heterologous nucleic acid sequence has an amino acid sequence as shown in SEQ ID: No. 5, SEQ ID: No. 6; SEQ ID: No. 7 and SEQ ID: No. 8.
[0150] Pharmaceutical insulin preparations can be prepared by purified insulin and / or purified insulin analogs, and such preparations can be used to treat diabetes. In general, purified insulin will be mixed with a pharmaceutically acceptable carrier or diluent, and its amount is enough to play a therapeutic effect without producing undesirable side effects to the patient receiving treatment. In order to prepare an insulin composition, the weight fraction of insulin is dissolved, suspended, dispersed or otherwise mixed in the carrier or diluent of selection at an effective concentration so that the disease being treated is improved. Pharmaceutical insulin preparations are preferably formulated for single dose administration. The therapeutic effective dose for parenteral delivery of human insulin is well known in the art. In the case of using insulin analogs or other delivery modes, the therapeutic effective dose can be easily determined empirically by those skilled in the art using known test protocols or by the extrapolation of in vivo or in vitro test data. However, it is understood that concentration and dosage can be different according to the severity of the disease alleviated. It should be understood that for any particular subject, a specific dosage regimen can be adjusted over time according to the individual judgment of the person administering or supervising the administration of the preparation.
[0151] The pharmaceutical solution or suspension may include, for example, a sterile diluent such as, for example, water, lactose, sucrose, calcium hydrogen phosphate or carboxymethylcellulose. The carrier that may be used includes water, saline, aqueous glucose, glycerol, ethylene glycol, ethanol, etc., to form a solution or suspension. If necessary, the pharmaceutical composition may also contain non-toxic auxiliary substances such as wetting agents; emulsifiers; solubilizers; antimicrobial agents such as benzyl alcohol and methyl paraben; antioxidants such as ascorbic acid and sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA), zinc ions; pH buffers such as sodium hydroxide, hydrochloric acid, acetate, citrate or phosphate buffer; and combinations thereof.
[0152] The final formulation of insulin preparations generally depends on the insulin delivery mode. Insulin prepared according to the disclosure can be delivered in any desired manner; however, parenteral delivery forms are considered to be the most likely delivery mode to be used. Insulin analogs produced by the method according to the disclosure can be used to treat states that are sensitive to insulin. Therefore, they can be used to treat type 1 diabetes, type 2 diabetes, and hyperglycemia, such as are sometimes seen in seriously injured persons and those who have undergone major surgery. Where convenient, insulin analogs can be used in combination with other types of insulin, such as insulin analogs with a faster onset of action. Examples of such insulin analogs are described in, for example, European patent applications with publication numbers EP 214826, EP 375437, and EP 383472.
[0153] Pharmaceutical compositions containing insulin analogs of the present disclosure can be used to treat states that are sensitive to insulin. Therefore, they can be used to treat type 1 diabetes, type 2 diabetes, and hyperglycemia, such as are sometimes seen in severely injured persons and those who have undergone major surgery. For any patient, the optimal dosage level depends on various factors, including the efficacy of the specific insulin analog used, the patient's age, weight, physical activity and diet, possible combinations with other drugs, and the severity of the state to be treated. It is suggested that those skilled in the art can determine the daily dosage of the insulin derivative for each individual patient in a manner similar to known insulin compositions. Example Example 1: HEK293 cell transfection or transduction
[0154] The procedures for introducing recombinant expression vectors into mammalian host cells (eg, HEK293) are well known in the art. Transformation of host cells can be performed by many procedures known to those skilled in the art, including non-viral methods or by viral vectors.
[0155] For non-viral transfection, 10,000 to 15,000 HEK293 cells were seeded in each well of a 24-well plate in 0.5 ml complete growth medium 12-24 hours before transfection. The cells were washed with PBS 1X and 0.5 ml fresh growth medium was added to each well. Transfection complexes were prepared by mixing 40 μl serum-free medium, 4.5 μl transfection reagent and (referring to the final volume including growth medium) 500 ng expression vector. The transfection complexes were incubated at room temperature (RT) for 15-30 minutes. 2 μl of complex condensing reagent was added. Complex condensing agents increase transfection efficiency by reducing the size of transfection complexes; however, it increases cytotoxicity. After incubation, the prepared transfection complexes were added to 0.5 ml complete growth medium per well of washed HEK293 cells. The cells were incubated with transfection complexes in a humidified CO2 incubator at 37°C. Use appropriate markers to select successfully transfected cells, for example by cell sorting (if fluorescent markers are used) or using antibiotic resistance markers or culture. 48-72 hours after transfection the fraction of successfully transfected cells is assayed for target gene expression.
[0156] For viral transduction, 4.5x10 6293T cells were split into 10cm culture dishes (9ml). On the day of transfection, 500ul total plasmid DNA (ug) was diluted. The transfer vector included viral packaging (psPAX2) at a ratio of 4:2:1 (respectively 6:3:1.5ug): viral envelope (pMD2G). 42ul of PEI (1ug / uL) was added to the diluted DNA and immediately mixed by pipetting up and down / vortexing. The volume of the PEI used was based on the PEI (ug) at a ratio of 4:1: total DNA (ug). The DNA / PEI mixture was incubated for 10-15 minutes at room temperature, and 500ul of the DNA / PEI mixture was added to each cell plate for overnight incubation. The culture medium was aspirated and the cells were washed once with preheated 8ml of PBS. The cells were then covered with preheated 9-10ml transfection medium (DMEM w / o phenol red, supplemented with 3% to 4% FBS and glutamine) and incubated for 18-24 hours. The viral supernatant is then collected and filtered with 0.22 μm and stored at 4°C. Optionally, the viral supernatant is dispensed into 50 ml conical tubes and spun overnight at 4°C, 8500 g, carefully aspirated (the precipitate may be loose), and resuspended at 100X in HBSS. The virus can be dispensed and stored indefinitely at -80. Inoculation and infection are performed when the HEK293 cell confluence reaches 50%-80%. The virus is thawed in a water bath. Polybrene is added to the viral supernatant at a final concentration of 6 ug / ml, and the viral supernatant / polybrene mixture is filtered in a 0.45 uM syringe filter. The cells are washed with 2 ml of fresh DMEM complete medium and 2 ml of the viral supernatant / polybrene mixture is added. The cells are spun at 1800 rpm (750 x g) for 1 hour at room temperature and incubated overnight at 37 degrees. All the culture medium in the wells is then aspirated and the cells are washed with 1X PBS. 2 ml of fresh DMEM complete medium was added to the cells. The cells were incubated for another 24 hours before trypsinization and analysis on FACS. Example 2 - Production of 50 / 500 ml human insulin analog on a shaker
[0157] HEK293 cells successfully transfected with the insulin analog construct were cultured using appropriate growth media and culture conditions and expanded to 0.5 × 10 in 500 ml of culture medium. 6 cells / mL. Fresh medium was added every 3-4 days as needed. The expressed insulin analog secreted into the growth medium was harvested after 1-4 weeks. Briefly, the medium was collected and filtered through a 0.22um filter. SDS Page gel was used to check for adequate protein production Example 3 - Purification
[0158] The insulin analog was precipitated from the growth medium in the following manner: zinc chloride solution (18%) was added to insulin glargine to a final concentration of 0.1%. The medium containing glargine was adjusted to pH 6.1, while the medium containing lispro was adjusted to pH 12.1 and incubated at 4°C for 16 hours, followed by centrifugation at 20,000×g for 30 minutes. The supernatant was removed and the precipitate containing insulin was collected. The precipitate containing glargine was resolved with sample buffer (7 M urea, 0.25 M acetic acid, pH 2.5) and insulin lispro (7 M urea, 0.25 M acetic acid, pH 5.5) and analyzed by ion exchange chromatography.
[0159] The insulin in the sample buffer was purified using a cation column equipped with Sp Sepharose Fast Flow resin (GE Healthcare Bio-Sciences, USA) onto an XK 16 column (GE Healthcare Bio-Sciences, USA) on an AKTA avant (GE Healthcare Bio-Sciences, USA). The buffer solution containing insulin was loaded onto a 50 ml SP Sepharose column at a flow rate of 1 ml / min, and the column was equilibrated with 10 CV (column volumes) of equilibrium buffer (7 M urea and 0.25 M acetic acid, pH 2.5 / 5.5) at a flow rate of 5 ml / min. With 10CV elution buffer A (7M urea and 0.25M acetic acid, pH2.5 / 5.5) with the flow velocity washing column of 5ml / min, then with 6CV elution buffer A and B (7M urea, 0.25M acetic acid and 1M sodium chloride, pH2.5 / 5.5) by using linear gradient (0-1M NaCl) with the insulin of 5ml / min flow velocity elution combination.Eluent is monitored at 280nm place, and each peak is collected in the fraction pipe.Use protein and peptide C4 analytical column to analyze the fraction collected by HPLC. Example 4 - Preparative High Performance Liquid Chromatography (Prep-HPLC):
[0160] Based on the purity analyzed by HPLC, fractions containing more than 60% insulin purity collected by cation exchange chromatography were collected.Preparative high performance liquid chromatography was carried out on an Agilent 1200 system (USA) equipped with a C8 prep HT column (21.2mm×150mm, particle size 5μm) (Agilent Technologies, USA).Solvent A was prepared by 0.25M acetic acid and 15% acetonitrile (ACN), and solvent B was prepared by 0.25M acetic acid and 45% ACN. The column was balanced with 10CV solvent A at a flow rate of 3ml / min and the collected protein was loaded onto the column at a flow rate of 1ml / min. After washing with 10CV solvent A at a flow rate of 3ml / min, the bound protein was eluted with 6CV solvent A and B at a flow rate of 3ml / min by applying a linear gradient (0%-70% solution B). The eluent was monitored at 280nm and each peak was collected.
[0161] The various embodiments described above may be combined to provide other embodiments. All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications mentioned in this specification and / or listed in the application data sheet are incorporated herein by reference in their entirety. If there is a need to adopt the concepts of various patents, applications, and publications to provide other embodiments, aspects of the embodiments may be modified.
[0162] These and other changes can be made to the embodiments in light of the above detailed description. In general, in the following claims, the terms used should not be interpreted to limit the claims to the specific embodiments disclosed in the specification and claims, but should be interpreted to include all possible embodiments and the full range of equivalents authorized by such claims. Therefore, the claims are not limited by the present disclosure.
Claims
1. A method for producing a functional recombinant protein (including insulin analogs and / or derivatives thereof) in its native conformation using a modified human proinsulin polypeptide in a competent host cell, comprising: (a) transforming a competent host cell with an expression vector, wherein the expression vector is suitable for the host cell and comprises a heterologous nucleic acid having a sequence encoding the modified human proinsulin polypeptide; (b) culturing the transformed host cell to express and secrete the insulin analog and / or its derivative in a growth medium; and (c) harvesting the secreted insulin analog and / or derivative thereof from the growth medium, wherein the secreted insulin analog and / or derivative thereof is a functional insulin analog and / or derivative thereof in its native conformation and is capable of binding to an insulin receptor peptide.
2. The method of claim 1, wherein the expression vector comprising the heterologous nucleic acid encoding the modified human proinsulin polypeptide further comprises a heterologous nucleic acid sequence encoding one or more agents for processing the modified proinsulin polypeptide into functional insulin.
3. The method of claim 2, wherein the one or more agents used to process the modified proinsulin polypeptide into functional insulin are selected from endoproteases and carboxypeptidases.
4. The method of claim 1, further comprising co-transforming the competent host cell with a second expression vector comprising a heterologous nucleic acid sequence encoding one or more agents for processing the modified proinsulin into functional insulin.
5. The method of claim 4, wherein the one or more agents used to process the modified proinsulin into functional insulin are selected from endoproteases and carboxypeptidases.
6. The method of claim 3 or 5, wherein the endoprotease is selected from the group comprising prohormone convertase 1 / 3 (PC1 / 3) and prohormone convertase 2 (PC2).
7. The method of claim 3 or 5, wherein the heterologous nucleic acid sequence encoding one or more agents for processing the modified proinsulin into functional insulin encodes the sequence of SEQ ID NO:
5.
8. The method of claim 3 or 5, wherein the heterologous nucleic acid sequence encoding one or more agents for processing the modified proinsulin into functional insulin encodes the sequence of SEQ ID NO:
6.
9. The method of claim 3 or 5, wherein the carboxypeptidase is carboxypeptidase E (CPE).
10. The method of claim 3 or 5, wherein the heterologous nucleic acid sequence encoding one or more agents for processing the modified proinsulin into functional insulin encodes the sequence of SEQ ID NO: 7 or 8.
11. A method as described in claim 2 or 4, wherein the heterologous nucleotide sequence encoding the modified human proinsulin polypeptide encodes the sequence of SEQ ID: NO.1; and wherein the one or more agents used to process the modified human proinsulin polypeptide into functional insulin comprise PC1 / 3 and CPE and optionally PC2.
12. The method of claim 11, wherein the heterologous nucleic acid sequence encoding one or more agents for processing the modified human proinsulin into functional insulin encodes the sequences of SEQ ID NO: 5 and SEQ ID NO: 7 or 8 and optionally SEQ ID NO:
6.
13. A method as described in claim 2 or 4, wherein the heterologous nucleotide sequence encoding the modified human proinsulin polypeptide encodes the sequence of SEQ ID: NO.3; and wherein the one or more agents for processing the modified human proinsulin polypeptide into functional insulin comprise PC1 / 3 and optionally PC2.
14. The method of claim 13, wherein the heterologous nucleic acid sequence encoding one or more agents for processing the modified human proinsulin into functional insulin encodes the sequence of SEQ ID NO:5 and optionally SEQ ID NO:
6.
15. The method of claim 13, further comprising the step of blocking endogenous carboxypeptidase E activity in the competent host cell.
16. The method of claim 15, wherein the blocking step comprises introducing a deletion or mutation into the endogenous CPE at position 202 of the sequence of SEQ ID NO: 9 in the competent host cell by CRISPR-based homologous recombination.
17. The method of claim 16, wherein the mutation at position 202 of the sequence of SEQ ID NO:9 is an S202P mutation.
18. The method of claim 15, wherein the blocking step comprises co-expressing a mutated CPE in the competent host cell, the mutated CPE having at least one mutation at a position selected from the group consisting of 72H, 75E, 147R, 192H, 202S, 243Y and 296E of the sequence comprising SEQ ID NO:
9.
19. The method of claim 15, wherein the blocking step comprises adding a blocking agent selected from the group consisting of dopamine quinine, dopamine, norepinephrine, epinephrine, potato carboxypeptidase inhibitor (PCI), a 9-mer peptide designated CPI-2KR, and a peptide encoding a decoy arginine sequence.
20. The method of any one of claims 1-19, wherein the expression vector is selected from a lentiviral vector system.
21. The method of any one of claims 1-20, wherein the competent host cell is a mammalian cell selected from the group comprising HEK293 cells, CHO cells, COS and HeLa cells.
22. The method of any one of claims 1-14 and 20, wherein the competent host cell is selected from the group consisting of algae and yeast.
23. The method of any one of claims 1-22, wherein the competent host cell comprises a genetic modification to promote the formation of stable disulfide bonds within the cytoplasm for processing of the modified proinsulin into functional insulin.
24. The method of any one of claims 1-23, wherein said step of harvesting said insulin analogue and / or derivative thereof comprises isolating said insulin from said transformed mammalian cell.
25. The method of any one of claims 1-24, wherein the insulin analogue and / or derivative thereof is produced continuously.
26. The method of any one of claims 1-25, wherein the insulin analog and / or derivative thereof is effective in treating diabetes, prediabetes and hyperglycemia.
27. Polynucleotide encoding (i) a modified human proinsulin polypeptide encoded by the sequence of SEQ ID: 1 or SEQ ID: 3; and (ii) at least one agent for processing said modified human proinsulin into functional insulin.
28. The polynucleotide of claim 27, wherein the at least one agent for processing the modified human proinsulin into functional insulin is selected from the group comprising endoproteases and carboxypeptidases.
29. The polynucleotide of claim 28, wherein the endoprotease is selected from the group consisting of PC1 / 3 and PC2.
30. The polynucleotide of claim 29, wherein the PC1 / 3 is encoded by the sequence of SEQ ID NO:
5.
31. The polynucleotide of claim 29, wherein the endoprotease is PC2.
32. The polynucleotide of claim 31, wherein the PC2 is encoded by the sequence of SEQ ID NO:
6.
33. The polynucleotide of claim 28, wherein the carboxypeptidase is a CPE.
34. The polynucleotide of claim 33, wherein the CPE is encoded by the sequence of SEQ ID NO: 7 or 8.
35. The polynucleotide of claim 27, wherein the modified human proinsulin polypeptide comprises the sequence of SEQ ID: NO.1; and wherein the at least one agent for processing the modified human proinsulin into functional insulin comprises PC1 / 3 and CPE and optionally PC2.
36. The polynucleotide of claim 35, wherein the at least one agent for processing the modified human proinsulin into functional insulin is encoded by the sequences of SEQ ID NO: 5 and SEQ ID NO: 7 or 8 and optionally SEQ ID NO:
6.
37. The polynucleotide of claim 27, wherein the modified human proinsulin polypeptide comprises the sequence of SEQ ID: NO.3; and wherein the at least one agent for processing the modified human proinsulin into functional insulin comprises PC1 / 3 and optionally PC2.
38. The polynucleotide of claim 37, wherein the at least one agent for processing the modified proinsulin into functional insulin is encoded by the sequence of and SEQ ID NO: 5 and optionally SEQ ID NO:
6.
39. The polynucleotide of claim 37, further encoding a blocker configured to block endogenous carboxypeptidase E activity.
40. The polynucleotide of claim 39, wherein the blocker comprises a mutated CPE having at least one mutation at a position selected from the group consisting of 72H, 75E, 147R, 192H, 202S, 243Y and 296E of the sequence comprising SEQ ID NO:
9.
41. An expression vector comprising the polynucleotide of any one of claims 27-40.
42. The expression vector of claim 41, wherein the vector is selected from a lentiviral vector system, 43. A modified host cell comprising the polynucleotide of any one of claims 27-40 or the expression vector of claim 41 or 42.
44. The modified host cell of claim 43, wherein the host cell is a mammalian cell.
45. The modified host cell of claim 43 or 44, comprising a genetic modification to promote the formation of stable disulfide bonds within the cytoplasm for processing of the modified proinsulin into functional insulin.
46. A modified host cell as described in any one of claims 43-45, wherein the modified host cell is selected from HEK293 cells, CHO cells, COS, and HeLa cells.
47. The modified host cell of claim 43, wherein the modified host cell is selected from the group consisting of algae and yeast.
48. A modified host cell as described in claim 44, further comprising a deletion or mutation of the endogenous CPE at position 202 of the sequence shown in SEQ ID NO:9 by CRISPR-based homologous recombination.
49. A modified host cell as described in claim 44, wherein the expression and / or activity of the endogenous CPE is reduced or eliminated.
50. The modified host cell of claim 44, wherein the mutated CPE is catalytically inactive.
51. A modified host cell as described in claim 44, wherein the mutated CPE binds but does not hydrolyze the C-terminal extension of the long-acting insulin B chain.
52. A method for treating diabetes in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the human insulin analog obtained by the method of claim 1.
53. A method for restoring blood glucose homeostasis in a subject in need thereof, comprising administering a therapeutically effective amount of the human insulin analog obtained by the method of claim 1.
54. A method for producing a protein in its native conformation in a host cell using a propeptide, comprising: (a) culturing the host cell recombinantly expressing the propeptide and protease under conditions sufficient for protein maturation and secretion; as well as (b) harvesting the secreted protein from the growth medium.
55. The method of claim 54, wherein the protein is selected from the group comprising insulin, amylin, gastrin, ghrelin, glucagon, somatostatin, α-MSH, ACTH and β-endorphin.
56. The method of claim 54, wherein the protease comprises an endoprotease and a carboxypeptidase.
57. The method of claim 56, wherein the endoprotease is selected from the group consisting of PC1 / 3 and PC2.
58. The method of claim 56, wherein the carboxypeptidase is CPE.
59. The method of claim 54, wherein the host cell comprises a mutated CPE having at least one mutation at a position selected from the group consisting of 72H, 75E, 147R, 192H, 202S, 243Y and 296E of the sequence comprising SEQ ID NO:
9.
60. The method of claim 55, wherein the mutant CPE is catalytically inactive, and wherein the catalytically inactive CPE protein binds but does not hydrolyze the protein.
61. The method of claim 54, wherein the protein is produced continuously.
62. The method of claim 58, wherein the expression and / or activity of the endogenous CPE protein is reduced or eliminated.
63. A modified mammalian host cell, wherein the modified mammalian host cell genome comprises a mutated CPE gene encoding a mutated CPE.
64. A modified host cell as described in claim 62, wherein the expression and / or activity of the CPE is reduced or eliminated.
65. A mammalian host cell as described in claim 61, wherein the mutated CPE is catalytically inactive.
66. A mammalian host cell as described in claim 61, wherein the mutated CPE binds but does not hydrolyze protein.
67. A polynucleotide encoding a mutated CPE, wherein the mutated CPE is catalytically inactive.
68. The polynucleotide of claim 67, wherein the mutated CPE binds but does not hydrolyze protein.
69. The polynucleotide of claim 67 or 68, wherein the mutated CPE comprises at least one mutation at a position selected from the group consisting of 72H, 75E, 147R, 192H, 202S, 243Y and 296E of the sequence comprising SEQ ID NO:
9.
70. A mutated CPE derived from the sequence of SEQ ID NO: 9, wherein the mutated CPE is catalytically inactive.
71. A mutated CPE as described in claim 70, wherein the mutated CPE binds but does not hydrolyze protein.
72. The mutated CPE of claim 70 or 71, wherein the mutated CPE comprises at least one mutation at a position selected from the group consisting of 72H, 75E, 147R, 192H, 202S, 243Y and 296E of the sequence comprising SEQ ID NO:9.
